January 30, 2023

Mr. Daniel Lee
Assistant U.S. Trade Representative for Innovation & Intellectual Property
Office of the U.S. Trade Representative
600 17th St., NW
Washington, DC 20508

Re: USTR 2023 Special 301 Review, Request for Public Comment (Docket No. USTR–2022-0016)

Dear Mr. Lee:

Intellectual Property Owners Association (IPO) appreciates the opportunity to provide comments regarding the U.S. Trade Representative’s (USTR’s) 2023 Special 301 Review. IPO’s comments highlight concerns with key issues surrounding the effective protection of intellectual property (IP) rights globally.

IPO is an international trade association representing a “big tent” of diverse companies, law firms, service providers and individuals in all industries and fields of technology that own, or are interested in, intellectual property (IP) rights. IPO membership includes over 125 companies and spans over 30 countries. IPO advocates for effective and affordable IP ownership rights and offers a wide array of services, including supporting member interests relating to legislative and international issues; analyzing current IP issues; providing information and educational services; supporting and advocating for diversity, equity, and inclusion in IP and innovation; and disseminating information to the public on the importance of IP rights.

IPO’s vision is the global acceleration of innovation, creativity, and investment necessary to improve lives. The Board of Directors has adopted a strategic objective to foster diverse engagement in the innovation ecosystem and to integrate diversity, equity, and inclusion in all its work to complement IPO’s mission of promoting high quality and enforceable IP rights and predictable legal systems for all industries and technologies.

The importance of the IP system has been especially evident during the pandemic. The incentives provided by the IP system have enabled innovators to build the infrastructure that has allowed them to devote the resources, technical knowledge, and know-how necessary to develop the solutions required to counter the pandemic. IP has enabled an unprecedented amount of innovation and facilitated collaboration between innovators and their partners. Companies have worked together to produce vaccines and needed respirators, for example. They have cooperated to provide technology to facilitate contact tracing, produce high quality personal protective equipment, improve testing, and create treatments for COVID-19. It is maintaining the IP system that will fuel the next generation of solutions. IP has also been instrumental in helping society adapt to the
impact of the pandemic, through technology advancements to facilitate connection and collaboration.

IPO’s comments are organized in three sections: (I) highlighted broad-based concerns, (II) country-specific concerns, in alphabetical order by country; and (III) concerns about the push to weaken IP rights within multilateral fora.

I. HIGHLIGHTED BROAD-BASED CONCERNS

IPO will first highlight a few high-level concerns with protection of intellectual property around the world, without intending to minimize problems not featured in this section. Among these concerns are (a) inadequate trade secret protection, (b) counterfeiting, (c) compulsory licensing, (d) weak patent enforcement, (e) genetic resources and traditional knowledge, and (f) data legislation.1

**Trade Secret Protection**

For years, Article 39 of TRIPS has required WTO members to ensure effective protection of trade secrets. In the years since TRIPS Article 39 was agreed (December 15, 1993),2 there have been insufficient efforts in many WTO member countries to bring the laws, regulations and enforcement environment up to compliance with the required standard.3 IPO suggests that improving the global environment for protection of trade secrets be one of the top priorities for the Special 301 Report and for further action. Further action should include, for example, setting high levels of trade secret protection as a requirement under bilateral or multilateral trade agreements, both in the negotiation and enforcement stages. Elements of effective protection of trade secrets and undisclosed information include at least minimum standards to fully implement obligations under TRIPS Article 39, adequate and effective remedies (such as injunctions and criminal penalties) to stop misappropriation of trade secrets, and prohibition of compulsory licenses of trade secrets.

As part of marketing authorization submissions for medicines, regulatory authorities require pre-clinical and clinical trial information demonstrating the safety and efficacy of a medicine, which includes trade secrets. Regulatory data protection (RDP) provides a minimum level of protection to innovators, during which time no unauthorized third party can rely on the data submitted by the innovator for regulatory approval. RDP recognizes the extensive time, effort, and cost of clinical studies required to ensure that drugs developed are safe and effective for

---


3 Even in the case of the EU, for example, compliance was long delayed, with the EU Trade Secret Directive (adopted June 8, 2016) not requiring national laws to implement the directive until June 9, 2018. See “Directive (EU) 2016/943 on the protection of undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use and disclosure.”
patients—and it provides critical incentives to engage in continued research and development of new innovative therapies. Unfortunately, several U.S. trading partners do not provide RDP or have inadequate RDP regimes. Examples include Argentina, Brazil, China, Egypt, India, and Turkey.

**Counterfeiting**

Counterfeiting is a global problem that affects more than a brand or brand owner. The sale and manufacture of counterfeit goods poses a significant health and safety threat to consumers throughout the world. Counterfeiting has well known links to organized crime, terrorism, and money laundering. IPO members have reported counterfeiting issues in countries such as Canada, China, India, Peru, Russia, South Africa, Thailand, Turkey, the United Arab Emirates, the United States, Vietnam, and the United Kingdom.

Ecommerce and social media platforms have made it easier for counterfeiters to sell counterfeit products. These platforms provide counterfeiters with an opportunity to engage with consumers throughout the world anonymously with very little effort. Many ecommerce and social media platforms allow counterfeit products to be displayed next to authentic products and in search results for related products. In many cases, consumers are not even aware they purchased a counterfeit product and only realize this after the product fails. The number of ecommerce platforms increase every year, making it easier for counterfeiters to move from one platform to another to avoid detection.

Many brand owners use vendors to help enforce their brands on ecommerce and social media platforms. Other brand owners cannot afford to do this and must rely on internal resources and the cooperation of the platforms where they find counterfeit products. Some platforms cooperate well with brand owners, while others are more difficult in this regard. More action is needed by ecommerce platforms to prevent the sale of counterfeit goods on their platforms and provide accurate information on the source of counterfeit goods. Governments also need to play a role in protecting consumers from the sale of counterfeit goods on ecommerce platforms. Unless ecommerce platforms are held liable when they sell counterfeit goods, there is no incentive for such platforms to put in place measures to both protect consumers and reduce the damage to brands as a result of the sale of counterfeit goods.

Over the past few years brand owners have seen counterfeiters increase the use of social media to sell counterfeit goods. For example, social media platforms are used often by counterfeiters to promote the sale of counterfeit goods. Once a counterfeiter engages with a customer through social media they switch to the use of, for example, WeChat, Telegram Messenger, or other messaging platforms to continue the conversation and finalize the sale. It is important that governments put in place measures to protect consumers from the use of social media platforms to sell counterfeit goods.

Customs offices throughout the world play a key role in offline enforcement by helping brand owners stop product from entering a country. However, effective border enforcement is not available in many countries. This lack of effective global border enforcement makes it easier for counterfeiters to ship counterfeit products throughout the world and focus their activities on countries with weak border and IP enforcement.
One of the issues that continues to be a challenge for brand owners is the use of free trade zones and free ports by counterfeiters to ship counterfeit goods from the location of manufacture to ports all over the world. Counterfeit goods travel through free trade zones and free ports and are transshipped through multiple ports. This allows counterfeiters to hide their true country of manufacture and also take advantage of countries where Customs protection for transshipped or in transit goods is known to be weak or non-existent. As an example, during the pandemic manufacturers of counterfeit 3M respirators used Hong Kong as the port to ship counterfeit respirators to countries such as Korea, South Africa, Peru, the United States, the UAE, and Saudi Arabia. In many cases counterfeit respirators manufactured in China were shipped from Hong Kong into a warehouse in a free trade zone in Korea where they were re-exported to Japan. It is difficult to get Customs to seize counterfeit goods in a free trade zone or goods in transit. The transshipment of goods needs to be carefully controlled and more scrutiny applied by Customs offices to goods in transit.

Countries in which effective anticounterfeiting mechanisms are lacking in one or more areas (e.g., border control, enforcement mechanisms, government support, etc.), include the following: Brazil, Canada, China, Colombia, Ecuador, India, Indonesia, Kuwait, Malaysia, Mexico, Paraguay, Philippines, Russia, Saudi Arabia, Singapore, Thailand, Turkey, United Arab Emirates, United Kingdom, and Vietnam.

**Compulsory Licensing**

The patent system drives and enables research and development that is delivering valuable new innovations to society, and it has facilitated an unprecedented amount of collaboration that is advancing solutions to the most pressing issues facing society today. However, several countries, such as Argentina, Brazil, Chile, Colombia, Egypt, Russia, Thailand, and Turkey, have adopted or are considering resolutions, laws, or regulations that promote or provide broad discretion to issue a compulsory license. Compulsory licenses have been issued in previous years in several countries, including Hungary, India, Indonesia, Israel, Malaysia, and Russia. Granting compulsory licenses undercuts the importance of a predictable and reliable patent system and undermines investment in innovative solutions that benefit society. IPO believes that licensing of IP rights is best accomplished through voluntary efforts.4

**Patent Enforcement**

Effective, efficient, and fair means for enforcing patents are foundational principles for a legal system to deliver the intended benefits of patent rights. Unreasonable barriers to patent enforcement include excessive evidentiary burdens for the initial complaint, statutory caps or limited damage awards, slow resolution of legal disputes, and the failure of courts to understand technical issues or IP-specific legal concepts. It is also foundational for a legal system to provide all parties with the ability to fully explore and resolve the merits of disputes in a balanced process.

---

IPO urges legislative and administrative reforms that allow patent holders improved access to legal systems by adopting reasonable complaint pleading and evidentiary requirements, establishing standards of proof that are aligned with the parties’ access to the relevant facts, and appointing experienced and competent judges to adjudicate patent matters. IPO further urges reforms to ensure patent proceedings in Court are held fairly and equitably, conclude within an appropriate timeline due to the time sensitivity of these claims, and appropriate legal changes are adopted to compensate patent holders for their losses in a case of proven infringement.

Additionally, mechanisms for resolution of patent disputes before marketing approval is granted for a generic or biosimilar product are important to support continued investment in the research and development that leads to new medicines. The premature launch of a medicine that is later found to infringe a patent may disrupt patient treatment and cause commercial damage to the innovative company that is impossible to repair later. IPO welcomes efforts by China to implement such a mechanism and hopes that efforts will be made to provide meaningful protection for innovators’ patent rights. Additional countries, such as India and Russia, among others, should also seek to implement such a mechanism. Countries such as Saudi Arabia that grant marketing approval to generic drugs during the term of the innovator’s patent prevent effective enforcement of patent rights and impair the incentives to invest in the development of drugs.5

**Genetic Resources and Traditional Knowledge**

Patent laws that impose patent disclosure requirements regarding the source and origin of genetic resources introduce uncertainties into the patent system that inhibit innovation in relevant technologies and undermine the potential of benefit-sharing. In some cases, compliance with such requirements is impossible, particularly where the existence or origin of any genetic resources incorporated into a product may be unknown or untraceable. IPO supports the objectives of the Convention on Biological Diversity (“CBD”) and recognizes the national sovereignty of States over biological resources. However, such patent disclosure requirements do not adequately address these issues, and instead diminish the potential for developing benefits to be shared. IPO believes these patent disclosure requirements implemented in various countries (e.g., China, India, Indonesia, Malaysia, Thailand and Columbia) introduce uncertainty for innovators and undermine the sustainable use of technology related to biological resources, and should be eliminated.

Genetic resources are now largely utilized in archived electronic digital sequence information (DSI) form and accessed from publicly available databases. Due to the voluntary nature of submissions to such existing genetic databases, the veracity of the source may not be reliable. Given that large and complex comparative genetics analyses are typically required for innovation, determining the correct apportionment of relative contributions is not practical. Further any requirements for *a priori* access and benefits sharing agreements create uncertainty in patent validity and administrative burden. Because special disclosure requirements for the source of genetic resources in patent applications do not further the goals of promoting

---

5 E.g., Saudi SFDA grant of marketing approval for a generic version of the Hepatitis Drug Daclatasvir during the term of the patent granted by the Patent Office of the Gulf Cooperation Council (which includes Saudi Arabia).
innovation and issuing valid patents to create benefits for sharing, IPO opposes such special genetics source disclosure requirements in patent laws.

Furthermore, unrestricted access to public collections of genetic DSI is essential to encourage innovation and promote scientific progress. Accordingly, IPO is concerned about suggestions to restrict access to public collections of DSI and to impose advanced mandatory benefit sharing mechanisms for the use of such DSI as it relates to patent laws, and opposes these proposals. Nations should consider the improvement and use of databases for the defensive protection of genetic resources and traditional knowledge associated with genetic resources. The erroneous granting of patents can be effectively addressed by improving databases for storing genetic resources and non-secret traditional knowledge associated with genetic resources that are used for prior art or reference material searches, as well as through utilizing certain existing institutional systems in coordination more efficiently.

Examples of concerning developments include proposed amendments to Malaysia’s IP laws and procedural barriers in Thailand. The proposed amendments to Malaysia’s IP laws include provisions for disclosure of traditional knowledge and genetic resources, as well as compulsory licensing, which raise concerns for genetics research-based industries. Thailand could impose procedural barriers by requiring applicants to disclose information regarding the use of genetic resources as part of their patent application. Such disclosure requirements could present significant barriers to patentability and should be removed.

**Data Legislation**

A range of actions and attention around legal rights in data have implications on IP rights. For example, automated decision-making tools have led to demands on sharing algorithms and data sets used for training. Country attention around information technology systems and network security have led to concerns around sharing trade secret data about system setup and security measures. China’s quickly evolving landscape of data security laws, cybersecurity laws, personal information protection laws, cross-border data transfer laws, and privacy more generally, has led to some demands to install “sniffers” in networks of private companies operating in China. Similarly, India’s Data Protection Bill purports to regulate data transfer very broadly through central controls with mandates around network/data monitoring equipment installation in private companies operating in India. The European Union’s draft Data Act seeks to regulate part of the data space by mandating that a data holder make content available to users of products or services. The EU General Data Protection Regulations (GDPR), require, *inter alia*, sharing meaningful information about the logic involved in automated decision-making protocols involving personal data, with recent cases involving technology used to match riders to drivers in ride-sharing Apps. The court decisions have gone both ways – requiring disclosure of logic, and protecting such disclosure. The positive intentions behind the efforts in overall data protection and privacy need to be balanced with a fundamental purpose of intellectual property rights - encouraging investment in innovation and progress.
II. COUNTRY-SPECIFIC CONCERNS

ARGENTINA

**Backlog Leading to Reduced Patent Value and Lack of Clarity of Rights**

The patent examination backlog in Argentina is challenging for innovators to manage. In general, the earliest that patent applications are resolved is five years, and for pharmaceutical and biotech inventions it can take up to ten to twelve years. Such delays in securing patent rights make it difficult for innovators to attract investors or support business plans. We welcome efforts by Argentina’s Patent Office to reduce the backlog, including the enactment of Resolution 56/2016, which might be characterized as an “internal” patent prosecution highway. Notwithstanding the efforts of Argentina’s Patent Office to reduce the backlog, a significant backlog remains. Argentina provides neither provisional nor supplemental protection to ameliorate the delays during prosecution.

**Shifts in the Legal Framework Creating Uncertainty for Innovators**

Argentina’s Patent Office enacted Resolution P-107/2012 in May 2012. This resolution introduced more restrictive patentability criteria for chemical and pharmaceutical inventions. The restrictive guidelines refuse pharmaceutical patents for: compositions and formulations, salts, esters and ethers, polymorphs, analogy processes, active metabolites and pro-drugs, enantiomers, selection patents and certain Markush-type claims. These criteria are inconsistent with Argentina’s obligations under the TRIPS agreement. When these criteria are combined with the substantial backlog, significant uncertainty results for innovators in the chemical and pharmaceutical areas.

**Increased Risk of Compulsory Licenses**

In December 2019, Argentina passed an Emergency Economic Law that would increase the likelihood of the grant of compulsory licenses being required by the Ministry of Health. The law would allow compulsory licenses as a mechanism to control price increases. Compulsory licensing, however, undermines the economic incentives created by the IP system for innovation and investment in research and development.

---

6 Resolución 56/2016, Instituto Nacional de la Propiedad Industrial.
Lack of Regulatory Data Protection

Argentina does not provide protection for regulatory test data, which is inconsistent with Argentina’s TRIPS obligations (Article 39.3). Specifically, Law 24,766 and Decree 150/92 permit Argentine officials to rely on data submitted by originators to approve requests by competitors to market similar products.

AUSTRALIA

Australia’s Heightened Utility and Onerous Best Method Requirements for Patents

Several court decisions have highlighted two areas in which Australian law is out of line with the Australia-U.S. Free Trade Agreement (AUSFTA) and with international practice. Australia fails to offer certain patent protections that it agreed to provide, which harms innovators seeking patent protection in Australia.

Despite the uncertainty of most types of innovation, Australia requires a patent to deliver all its “promised benefits.” If a patentee describes two potential advantages of an invention and only one turns out to be achievable, the resulting patent will be found invalid. Besides serving as an inequitable ground for denying a patent, the outcome is inconsistent with the Free Trade Agreement, which requires Australia to protect inventions with “a specific, substantial, and credible utility.”

Another unusual feature of Australian law is its “best method” requirement. An independent ground for invalidity, patent applicants must describe the best method known to them at the time of filing the complete application. What amounts to the complete application will depend on the filing strategy that the patentee adopts. In any case, this requirement complicates matters for applicants who do not update the first filed application before foreign filing. Such a requirement is inconsistent with international practice, and harms U.S. inventors seeking to protect their inventions in Australia.

Several recent cases have confirmed the continued applicability of the best method requirement. The Federal Court considered the best method requirement in BlueScope Steel Ltd. v Dongkuk Steel Mill Co., Ltd. The Court found that the patents at issue were invalid for failing to disclose the best method known to the applicant at the date of filing the complete application. The Court also considered the best method requirement in Dometic Australia Pty Ltd. v. Houghton Leisure Products Pty Ltd. In this case, the Court found that the best method requirement is based on what was known by the Applicant at the date of filing of the application (not the filing date of any earlier parent or priority application). In this case, the date

13 Australia-U.S. Free Trade Agreement, Art. 17.9.13.
15 BlueScope Steel Ltd. v Dongkuk Steel Mill Co., Ltd. (No 2) [2019] FCA 2117 (17 December 2019).
of filing was the date on which a divisional was filed, not the date on which the parent PCT application was filed. More recently, *Dometic* was cited with approval in *Axent Holdings*.

The Federal Court in *Merck Sharp & Dohme Corp. v. Wyeth LLC (No 3)*,17 recently construed the requirement of support in a manner that is inconsistent with Article 17.9(12) of the AUSFTA. Under the court’s approach, unduly specific disclosures are required in the specification before a claimed invention can be said to be “sufficiently supported.” This requires the specification to disclose a technical contribution to the art that justifies the breadth of the claims.

**Patentable Subject Matter in Relation to Computer-Implemented Inventions**

In Australia, there is uncertainty regarding patentable subject matter in relation to computer-implemented inventions. A key difficulty has been the Federal Court of Australia’s confirmation in a plethora of recent decisions that, once the Court established that the alleged invention is a computer-implemented invention, it must also be shown that the alleged invention represents an advance in computer technology in order for the alleged invention to be patentable subject matter.18 This approach has resulted in claims that have been found allowable in the U.S. being rejected in Australia, even when examined under the Patent Prosecution Highway. Such unpredictability has been to the detriment of those who innovate in this space.

The High Court of Australia recently grappled with this issue in *Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents*.19 Although the long-awaited High Court decision had been expected to clarify (and potentially change) the current practice adopted by the Australian Patent Office, the bench was split evenly as to what approach should be taken. As a result, under the Judiciary Act 1903 (Cth), the appeal was dismissed and the lower court ruling stands albeit without being binding precedent.20 Despite this, each Justice of the High Court rejected the Full Court of the Federal Court of Australia’s requirement for there to be an advancement in computer technology for the invention to be patentable subject matter. The Patent Office has stated that, at least for now, an invention will not be patentable “if it is merely directed to the implementation of an otherwise unpatentable idea in conventional and well-understood computer technology”.21 However, it remains uncertain how the current examination practice may change in the future, or if it will change at all.

---

17 *Merck Sharp & Dohme Corp. v. Wyeth LLC (No 3)* [2020] FCA 1477, affirmed by the Full Federal Court of Australia in *Jusand Nominees Pty Ltd v Rattlejack Innovations Pty Ltd* [2022] FCA 540. See also *Cytec Industries Inc v Nalco Company* [2021] FCA 970.

18 *Commissioner of Patents v Aristocrat Technologies Australia Pty Ltd* [2021] FCAFC 202; *Repipe Pty Ltd v Commissioner of Patents (No 3)* [2021] FCA 31; *Encompass Corporation Pty Ltd v InfoTrack Pty Ltd* [2019] FCAFC 161; *Commissioner of Patents v Rokt Pty Ltd* [2020] FCAFC 86.

19 *Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents* [2022] HCA 29.

20 Chief Justice Kiefel, and Justices Gageler and Keane dismissing the appeal by reason of a technical majority under section 23(2)(a) of the *Judiciary Act 1903* (Cth); Justices Gordon, Edelman and Steward allowing the appeal.

21 *Aristocrat Technologies Pty Ltd v Commissioner of Patents* [2022] HCA 29

Market-Size Damages

Australia’s Department of Health has implemented a policy by which it seeks damages from biopharmaceutical innovators that commence proceedings to enforce their patents and obtain a preliminary injunction but are ultimately unsuccessful on the merits. These damages are designed to compensate Australia’s pharmaceutical reimbursement scheme (PBS) for any delay in the reduction in PBS prices during the period of the preliminary injunction. The PBS imposes automatic and irreversible price cuts on medicines as soon as a first competing brand enters the market, but there is no corresponding mechanism for automatic compensation for innovators as a result of the PBS price cut if an infringing product is launched prematurely; the innovator must instead seek to recover those losses from the infringing generic as part of its damages claim.

Nevertheless, in a 2020 case, the Department of Health was unsuccessful in seeking compensation as a result of a generic company being restrained from supplying products in Australia and obtaining a PBS listing of such products. This case turned on findings of fact that, but for the interlocutory injunction, the generic company would not have applied for PBS. Therefore, this finding does not prevent the Commonwealth from establishing that a relevant party would have sought and obtained PBS listing of its products in future cases – it will necessarily depend on the nature and strength of the evidence.

This “market-size damages” approach has issues. It tips the scales in commercial patent disputes by exposing patentees to significant compensation claims and thus may discourage innovators from enforcing their patents. It means that the same government that examined and granted a patent (albeit through different government entities) can seek damages from the patentee for unsuccessfully trying to enforce it.

Biopharmaceutical innovators must be able to rely on and enforce patents issued by competent government authorities. Laws or policies that allow governments or other non-parties to a patent dispute to collect market-size damages undermine legal certainty, predictability, and the incentives patents provide for investment in new treatments and cures.

IPO encourages the Australian Government to take steps to increase the period of notification a patent holder receives regarding entry of a generic competitor, in an effort to reduce the need for emergency injunctive action. Nonetheless, the ongoing existence of the market-sized damages policy remains an obstacle to innovation and investment.

---

23 The claimed damage must have "necessarily and naturally flowed" from the interlocutory injunction for it to be recoverable.
24 Commonwealth of Australia v Sanofi (formerly Sanofi- Aventis) (No 5) [2020] FCA 543 (28 April 2020),
Shift Relating to Injunctions

In the patent litigation context, there has been a recent shift in the Australian courts negatively impacting the likelihood an interlocutory injunction would be granted.\(^{25}\) This is partly due to the perception that it would be more difficult to calculate potential losses for a generic company challenging a patent than to calculate a patentee’s losses. The primary consideration in determining whether to grant an injunction is where the balance of convenience lies. This looks at the detriment caused by granting or not granting the injunction on each party and whether damages would be an inadequate remedy to compensate for that detriment. Patentees, in recent cases, have been required to demonstrate the strength of their validity case. This approach in Australian courts is inconsistent with the provisional measures in Article 17.11(18) of the AUSFTA which provide that there is a rebuttable presumption that a patent is valid.

Weak Regulatory Data Protection

Australia provides regulatory data protection (RDP) of 5 years for small molecule and biologic products; however, Australia does not provide RDP relating to the registration of new formulations, combinations, indications, populations, or dosage forms of currently registered therapeutic goods.\(^{26}\) The lack of data protection for product changes supported by new clinical information, and the lack of protection for more than 5 years for biological products, potentially puts pharmaceutical innovators at a disadvantage in Australia in comparison to other developed countries. After expiry of the initial 5-year period, generic competitors can rely on innovators’ clinical data to obtain abridged approvals without delay (subject to any patent protection). Thus, the Australian data protection system does not adequately reward innovators for the cost of obtaining the clinical data to support the approval of product changes for the benefit of Australian patients.

Removal of IP Rights Exemption from Australian Competition Law

IPO is concerned about the removal of the exceptions to Australian competition law for agreements relating to IP rights. Specifically, Section 51(3) of the Competition and Consumer Act 2010 (Cth), which exempted certain conditions in intellectual property licenses from some competition law prohibitions, was repealed on 13 September 2019. Licensors and licensees may now be held criminally liable for breaching cartel prohibitions, unless the anti-overlap provisions apply, if the agreement contract includes price, territorial or quota restrictions. The position of licensors and licensees needs to be clarified.

\(^{25}\) See Biogen International GmbH v Pharmacor Pty Ltd [2021] FCA 1591. However, there have been a number of recent decisions where interlocutory applications were granted in the context of trademark proceedings. See The Cultural Intelligence Project Pty Ltd v The Entourage Education Group Pty Ltd [2021] FCCA 504, RB (Hygiene Home) Australia Pty Ltd v Henkel Australia Pty Ltd [2021] FCA 1094, and Martin & Pleasance Pty Ltd v A Nelson & Co Ltd [2021] FCAFC 80.

\(^{26}\) Therapeutic Goods Act 1989 (Cth) s 25A.
When Trademark Applications are inadvertently filed in the incorrect name, the defect is fatal

The Australian Federal Court in *Pham Global Pty Ltd v Insight Clinical Imaging Pty Ltd* [2017] FCAFC 83 made it clear that when trademark applications are filed in the incorrect name in Australia, the defect is fatal and cannot be cured by amendment. Accordingly, it is vital that trademark owners ensure that valid rights have been secured. A remedy is needed for instances of clerical error upon filing.

**BRAZIL**

Accession to the Hague Agreement for the International Registration of Industrial Designs

In October 2022, both houses of the Brazilian Congress concluded the approval of Brazil’s accession to the Hague Agreement on the international registration of industrial designs, which simplifies procedures and reduces costs for users of the system. After Mexico, Brazil should become the second country in Latin America to enter the agreement. Accession to the agreement is part of the government’s strategic agenda to modernize the Brazilian IP system, which also led to the accession to the Madrid Protocol in 2019. This is a positive development.

Compulsory Licensing Laws and Forced Technology Transfer

Brazil’s recent modifications to the rules governing compulsory licenses are concerning to IP owners. Of particular concern were forced technology transfer provisions that were proposed during the legislative process (but ultimately vetoed by the President).

IPO strongly opposes compulsory licensing of intellectual property rights with respect to all industries and technologies. Although IPO recognizes that compulsory licenses of IP rights may be legally permissible in limited and rare situations, IPO believes that licensing of IP rights is best accomplished through voluntary efforts.

Further, forced technology transfer could jeopardize IP rights and violate international treaties. As explained in the U.S. Trade Representative’s 2022 Special 301 Report, such transfers “disadvantage U.S. companies,” “discourage foreign investment in national economies,” and “slow the pace of innovation and economic progress.”

Patent and Trademark Application Backlogs

In Brazil, utility patent applications regularly remain pending far longer than in most other patent offices around the world. The lengthy backlog hurts innovators by complicating investment decisions and often impairing access to critical funding, especially for smaller companies. Such delays hurt both would-be patent owners and potential competitors, adding to market uncertainty and increasing the cost of innovation. This situation, however, has seen recent improvement through the implementation of various strategies, such as hiring additional

---

27 *Supra* note 4.
examiners, creating fast-track programs such as PPH agreements, and leveraging examination of foreign counterpart applications. Although these developments are very encouraging, it is important to continue to build on this momentum and reduce patent application pendency times.

With respect to trademarks, both the backlog and the examination period have decreased substantially. Thanks to Brazil’s accession to the Madrid Protocol in July 2019, its National Institute of Industrial Property, INPI, has implemented the changes necessary to comply with international standards. Trademarks are now being granted in 6 months on average.

**Proposed Patent Term Adjustment for INPI Delay**

Brazil should reinforce the above-described efforts to reduce patent examination backlogs by establishing a mechanism to restore patent term lost due to unreasonable delays during patent examination. Currently, due to the Supreme Court’s decision to eliminate sole paragraph of Article 40, patent applicants have no recourse to address such delays. The time has come for Brazil to establish a patent term adjustment mechanism to restore patent term lost due to unreasonable delays in the patent examination process.

In July 2022, a bill was submitted at the Brazilian House of Representatives to amend the patent statute towards the establishment of a patent term adjustment system (PTA) based on INPI’s delays during examination (PL No. 2.056/2022). According to the bill, patentees would be able to request PTA when INPI takes more than 60 days to issue decisions; the adjustment being limited to additional 5 years of patent protection. The bill is pending.

**Lack of Regulatory Data Protection**

Brazilian law provides data protection for veterinary, fertilizer, and agrochemical products, but does not provide similar protection for pharmaceutical products for human use, resulting in discriminatory treatment. Contrary to TRIPS Article 39, Brazil continues to allow government officials to grant marketing approval for pharmaceuticals to competitors relying on test and other data submitted by innovators to prove the safety and efficacy of their products. Additional efforts are needed to provide certainty that test data and other data will be fully protected against unauthorized use to secure marketing approval for a fixed period.

**CANADA**

**Patented Medicines Price Review Board (PMPRB) Regulations**

The PMPRB’s authority and mandate under the Patent Act is to ensure that patentees of patented medicines do not abuse their patent rights by selling patented medicines at excessive prices.

IPO has concerns about the Regulations Amending the Patented Medicines Regulations (the “Regulations”) that came into force on July 1, 2022. IPO is particularly concerned about

---

29 See Law 10.603/02
changes to the list of comparator countries under section 4(1)(f)(iii) of the Regulations that removed the United States and Switzerland and added Australia, Belgium, Japan, Netherlands, Norway, and Spain. The removal of the U.S. and the absence of other countries such as Mexico, another one of Canada’s largest trading partners, is concerning. Also troubling is the selection of countries for the list that in general have lower drug prices than Canada without considering the impact this has on accessibility to new medicines in those jurisdictions. Furthermore, the U.S. and Switzerland are home to many of the world’s pharmaceutical and biotechnology research companies, sending a message that Canada is interested in the benefits of that research, but not in compensating or incentivizing the research necessary to create the benefits.

IPO is also concerned about the reduction in reporting requirements for patented generic medicines (approved by means of Abbreviated New Drug Submission (“ANDS”)). Generic medicines are exempt from the continual reporting of information unless requested by the Patented Medicine Prices Review Board (“PMPRB”). At the same time, innovative manufacturers have expansive reporting requirements, triggered by having any patent that “pertains to a medicine” as falling within the jurisdiction of the PMPRB, while the PMPRB continues to support an even more expansive patent reporting scope.31

The Regulations unnecessarily discourage innovation and increase reporting requirements for innovative patent holders. When incentives for patent innovation are diminished, particularly in a major market like Canada, the value of intellectual property is negatively impacted for all types of patent owners everywhere. Simply put, Canada’s system is that of a free-rider with Canada unwilling to pay its share of the research and development costs of pharmaceuticals. These concerns are heightened when reference to Canada’s patent statute is used as the basis for lowering prices for patent-protected technologies as it raises the likelihood that similar regulations could be extended to other consumer goods.

Further, IPO is concerned that referencing a patent statute as a basis for placing patentees at an economic disadvantage compared to non-patent holders sets a troubling and disincentivizing precedent. Indeed, it is not surprising that many patentees are likely considering abandoning patents to avoid coming under the jurisdiction of the PMPRB. Other manufacturers may choose to withdraw from Canada, assuming they elect to enter, which further heightens the weakness of Canada’s pricing mechanism.

Weak Patent Enforcement

The Patented Medicines (Notice of Compliance) Regulations32 (the “PMNOC Regulations”) include deficiencies that weaken Canadian patent enforcement, including insufficient time for final patent determinations in a single proceeding, increasing liability for damages under section 8 (e.g., granting damages in excess of 100% of the total generic market, as discussed

31 The PMPRB has found that the phrase “pertains to a medicine” in section 79(2) of the Patent Act should be given a broad interpretation, whereby an invention that is the subject of a patent may “pertain to a medicine,” and therefore come under PMPRB jurisdiction, even if the invention does not encompass the medicine.

further below), and a separate litigation track for some types of patents due to their ineligibility for listing on the Patent Register (e.g., arbitrary timing requirements).

45 Days for Action on Notice of Allegation

The PMNOC Regulations provide that if a proceeding is not brought within the 45-day timeline after a patent is listed on the Patent Register and a Notice of Allegation (NOA) has been sent, then one cannot bring a proceeding under the Patent Act, unless the innovator had a reasonable basis for not bringing the action in response to the NOA.33 This provision has the effect of revoking a statutorily granted patent right due to a missed deadline, and puts on the patentee the onus of showing that there was something justifiably irregular in failing to sue at first instance.

Excessive Damages

IPO is also concerned about the potential expansion of liability for pharmaceutical innovators. Innovative companies are potentially liable under section 8 and common law theories, including for treble damages, in cases proceeding within the provincial courts of Ontario and Quebec.

The PMNOC Regulations explicitly consider all plaintiffs in the infringement action to be jointly and severally liable for losses suffered by the “second person”34 as opposed to only the “first person”35 under the previous regulations. However, there is no requirement for all second persons in NOC proceedings related to the same patented medicine to bring their section 8 claim together. Furthermore, there has been no amendment to allow the Court to consider multiple section 8 claims together and make findings related to multiple generic companies entering the market in the absence of the PMNOC Regulations, as does happen in the real world. As a result, when innovators face multiple section 8 claims, there is a risk that the defendant (innovator) will be subject to a cumulative damage award based on what cannot possibly occur in the real world.36 Also, the PMNOC Regulations do not impose any limits to the period of a first person’s liability under section 8 of the Regulations. Thus, second persons under the PMNOC Regulations may be able to claim losses suffered beyond the date of any dismissal or discontinuance. Taken together, the common law and section 8 related amendments create a risk of “windfall” damage awards. Furthermore, such awards are contrary

33 Patented Medicines (Notice of Compliance) Regulations, sections 6(1) and 6.01.
34 A “second person” means the person referred to in subsection 5(1) or (2) who files a submission or supplement referred to in those subsections. (seconde personne),” Patented Medicines (Notice of Compliance) Regulations, 2 (1), https://laws-lois.justice.gc.ca/eng/regulations/SOR-93-133/page-1.html#h-949984; “5 (1) If a second person files a submission for a notice of compliance in respect of a drug and the submission directly or indirectly compares the drug with, or makes reference to, another drug marketed in Canada under a notice of compliance issued to a first person and in respect of which a patent list has been submitted . . . ,” https://laws-lois.justice.gc.ca/eng/regulations/SOR-93-133/page-2.html/docCont.
35 A “first person” means the person referred to in subsection 4(1); (première personne),” Patented Medicines (Notice of Compliance) Regulations, 2 (1), https://laws-lois.justice.gc.ca/eng/regulations/SOR-93-133/page-1.html#h-949984; 4 (1) “A first person who files or who has filed a new drug submission or a supplement to a new drug submission may submit to the Minister a patent list in relation to the submission or supplement for addition to the register,” https://laws-lois.justice.gc.ca/eng/regulations/SOR-93-133/page-1.html#h-949984.
36 An example of this is seen in the cases of Apotex v. Sanofi-Aventis, 2014 FCA 68 and Teva Canada v. Sanofi-Aventis, 2014 FCA 67.
to the traditional compensatory function of damages and, in situations of section 8 damages in excess of 100% of the total generic market and/or potential treble damages, constitute a punitive award which is inconsistent with the limited remedy of declaratory relief currently provided for under Section 60(1) of the Patent Act, and would be an inequitable result.

**Certificate of Supplementary Protection (CSP) Restrictions**

Although it is positive that Canada has recently provided for restoration of patent terms for pharmaceutical inventions, under certain circumstances, by means of a Certificate of Supplementary Protection (“CSP”), IPO is concerned that there is still a bar to certain types of innovations being CSP eligible, including, for example, process and formulation patents. Overly restrictive eligibility criteria result in the exclusion of otherwise worthy patents from receiving a CSP and would likely discourage innovation.

In addition, the requirement that the innovator file their complete new drug submission in Canada within a year of filing in the U.S or Europe (or several other smaller markets) is overly restrictive, especially with respect to smaller companies who do not have the resources to file in multiple jurisdictions before they receive an indication of whether their submission is sufficient to receive approval. Both of these restrictive requirements are unlike patent term restoration requirements in other jurisdictions.

Furthermore, Canada’s term for a CSP is capped at two years of the possible five – an unduly restrictive time limit.

Finally, the CSP does not grant the full bundle of patent protections during the CSP period by providing a “manufacture for export” exception, i.e., it is not an act of infringement during the CSP period to make, construct, use or sell the patented medicine for the purpose of export from Canada.

**Multiple and Conflicting Certificate of Supplementary Protection Applications**

IPO is concerned that there remains a significant risk under the current CSP regime for unnecessary conflicts between patent owners. Under the current CSP regime, one or more third parties are allowed to seek a CSP based upon the Notice of Compliance (“NOC”) obtained by the pharmaceutical innovator. As Canadian law mandates only one CSP per drug, this “conflict” between one or more CSP applications citing the same NOC is resolved in an unnecessary and costly proceeding. Pharmaceutical innovators (the “NOC” holders) are concerned that the “conflict proceeding” may unjustly favor the third party. As a result, pharmaceutical innovators face a significant risk of losing the CSP to a third party thereby denying pharmaceutical innovators the incentive and reward for undertaking the costly and risky journey of drug development. IPO urges that third parties not be allowed to seek CSPs using a pharmaceutical innovator’s NOC without the permission of the innovator.

**Lack of Interlocutory Relief**

In the event a patentee pursues an action for infringement, it may apply for an interlocutory injunction to maintain its rights and, in particular, to prevent the market entry of the generic
product or to seek its withdrawal from the market. These applications, however, rarely succeed in Canada, even when there is compelling evidence of infringement. This is because the extremely high standard applied by the Canadian courts for the necessary finding of “irreparable harm” is essentially impossible for innovative pharmaceutical companies to meet. Although the PMNOC Regulations provide for a 24-month statutory stay, it often takes at least that amount of time before an action for patent infringement is tried, and even longer to obtain damages. An innovator is thus placed with a Hobson’s choice of surrendering its procedural rights or obtaining meaningful injunctive relief. If the innovator maintains its procedural rights, then the marketing of the generic product can almost completely erode the innovative company’s market share. Provincial and private payer policies mandating the substitution of generics for brand-name products guarantee rapid market loss.

These various deficiencies frequently result in violations of the patent rights of pharmaceutical companies operating in Canada with attendant, and often irreparable, economic losses. This lack of availability of interlocutory injunctions calls into question Canada’s compliance with Article 50 of TRIPS, as well as the United States-Mexico-Canada Agreement (USMCA), Article 20.51, paragraph 1(c).

**Limitation of Listing of Valid Patents and Inequitable Listing Requirements**

Patent owners continue to be prevented from listing their patents on the Patent Register per Patented Medicines (Notice of Compliance) Regulations when the patents do not meet certain, seemingly arbitrary, timing requirements. These timing restrictions are not present in the U.S. under the Hatch-Waxman Act. The effect is to deny pharmaceutical innovators access to enforcement procedures in the context of early working for any patent not meeting these listing requirements.

**Introduction of the Promise Doctrine into Allegations of Overbreadth**

The promise doctrine involved the Court identifying the utility that is alleged to be “promised” in the patent specification, and then measuring the utility of the invention against those promises. In 2017, the Supreme Court of Canada (“SCC”) rejected this approach in

---

37 See, e.g., Merck & Co. v. Apotex Inc. (2013 FC 751) (On 16 July 2013, the Federal Court released a decision granting the largest award of damages for patent infringement in Canadian history. Although the award quantum was widely reported, less reported was that the case dated back to 1993 when Apotex first served a Notice of Allegation in which it undertook not to infringe Merck’s patent if it obtained a Notice of Compliance. This judgment was also appealed, further delaying any eventual damages award.)

38 “If a Party permits, as a condition of approving the marketing of a pharmaceutical product, persons, other than the person originally submitting the safety and efficacy information, to rely on evidence or information concerning the safety and efficacy of a product that was previously approved, such as evidence of prior marketing approval by the Party or in another territory, that Party shall provide:... (c) procedures, such as judicial or administrative proceedings, and expeditious remedies, such as preliminary injunctions or equivalent effective provisional measures, for the timely resolution of disputes concerning the validity or infringement of an applicable patent claiming an approved pharmaceutical product or its approved method of use.” See https://usmca.com/intellectualproperty-rights-usmca-chapter-20/.


AstraZeneca, calling the doctrine “unsound.” The SCC held that the promise doctrine was “excessively onerous” on patentees, as it improperly imported disclosure requirements into the utility analysis, requiring that any disclosed use be demonstrated or soundly predicted at the filing date, regardless of what was included in the claims or the nature of the invention.

Despite rejecting the promise doctrine as part of the utility requirement, the SCC held that the “scheme of the Act treats the mischief of overpromising in multiple ways.” The Court, in paragraph 46 of its opinion, specifically stated a number of potential groundings for this potential mischief, including, inter alia, overbreadth. These statements in paragraph 46 have become the foundation of a number of allegations of invalidity from patent challengers. In particular, IPO is concerned that Canadian courts are introducing a version of the promise doctrine into determinations of overbreadth, thereby reintroducing the uncertainty of the promise doctrine into the law, and lowering the threshold for findings of overbreadth without any statutory basis for doing so.

In Canadian patent law, a claim is overbroad if it is broader than the invention disclosed in the patent’s specification, or broader than the invention made by the inventor. Alleged infringers are gaining traction by arguing that a claim is overbroad when certain elements of embodiments described in the specification are not included in the claims.

The Federal Court of Appeal (“FCA”) in a recent decision, Seedlings Life Science Ventures, stated that

“[i]t is apparent that determining that a feature of an invention is essential is a distinct exercise for the purpose of overbreadth than for the purpose of claim construction. For overbreadth, the focus is not whether omitting or changing the feature avoids the claim (as it is for claim construction), but rather whether that feature is so key to the invention described in the disclosure that a claim that omits it encompasses embodiments that were not contemplated in the disclosure… The challenge in the present appeal is in determining which elements go to the core of the invention such that their absence from the claims results in invalidity for overbreadth.”

Therefore, the FCA is inviting zealous lawyers to read a patent specification in such a way as to persuade a Court as to the nature of the “core of the invention.” This introduces a similar approach to, and therefore similar uncertainties and onerousness on patentees as, the rejected promise doctrine.

41 Id. at para 36.
42 Id. at para 37.
43 Id. at para 44.
44 Id. at para 46.
45 Western Oilfield Equipment Rentals Ltd et al v M-I LLC, 2021 FCA 24 at para 128.
46 Seedlings Life Science Ventures, LLC v Pfizer Canada ULC, 2021 FCA 154 at paras 54, 60.
47 Pfizer Canada Inc v Mylan Pharmaceuticals ULC, 2012 FCA 103 at para 57. See also Aux Sable Liquid Products LP v. JL Energy Transportation Inc., where the FC invalidated a patent due to overbreadth. In that decision, the Court disregarded that an embodiment that was disclosed in the patent was encompassed by the claims, instead finding that the claims did not cover other embodiments which it found amounted to the “invention disclosed in the patent,” as described in the specification (paras 58-60, 65-66).
**Elevating the Disclosure Requirement for Patents**

IPO is concerned that the FCA has elevated the disclosure requirement for patents. In *Seedlings*,\(^{48}\) the FCA stated that: “the disclosure must teach the skilled person to put into practice all embodiments of the invention, and without exercising inventive ingenuity or undue experimentation.”\(^ {49}\) It then found that the patent at issue for an apparatus for auto-injection of medication was invalid on that basis. The FCA found that the patent omitted from the claims certain preferred elements from embodiments that were described in the disclosure. The disclosure did not describe how to make embodiments other than the preferred embodiment.\(^ {50}\) This increased disclosure requirement adopted by the FCA appears to place an unmanageable burden on inventors to disclose all embodiments of an invention.

Further, this could mean that any inventive improvement on a first patent that falls within that first patent’s claims would make that first patent invalid. The improvement would fall within the scope of the first patent’s claims, but if inventive, the embodiment would not have been disclosed in the first patent by definition.\(^ {51}\) This elevated disclosure requirement is novel, and would place undue burden on innovators to meet the requirements for a valid patent.

**Lack of Adequate Trade Secret Protection**

The USTR Special 301 Report has persistently noted Canada’s lack of trade secret legislation as part of a robust intellectual property enforcement regime. In 2020 Canada took an important, but ultimately incomplete step to correct this deficiency. Pursuant to its obligations under the United States-Mexico-Canada (USMCA) trade agreement, Canada enacted new Criminal Code provisions related to trade secrets which came into force on July 1, 2020. These new provisions are aimed at the intentional theft of trade secrets and require proof of “deceit, falsehood or other fraudulent means” and the knowing obtainment or communication of a trade secret (Article 391(1)). Anyone convicted of these new offences (or related offences of conspiracy or attempt to commit or being an accessory after the fact in relation to the theft of a trade secret) can be punished either by way of an indictable offence (with imprisonment for a term not exceeding 14 years), or a summary conviction (Article 391(3)).

While this development in the protection of intellectual property in Canada is an important step, it ultimately does little to provide an effective enforcement option for trade secret rights holders. First, to the best of IPO’s knowledge, no prosecutions have taken place under these new provisions. Second, while the new Criminal Code focuses on intentional acts of fraud, this provides no protection to a trade secret rights holder pursuing an unintentional or mistaken breach of confidence. In these instances, Canada’s lack of statutorily-granted civil right of action continues to be problematic. In Canada (except in Quebec), one continues to have to resort to common law causes of action for breach of confidence, which according to a leading

---

\(^{48}\) *Seedlings Life Science Ventures, LLC v Pfizer Canada ULC*, 2021 FCA 154.  
\(^{49}\) *Id.* at para 68.  
\(^{50}\) *Id.* at para 71.  
commentator “remains a significant challenge for litigants.” Unlike its largest trading partner, Canada has yet to codify the basic principles of common law trade secret protection in a uniform manner, like the U.S. federal Defend Trade Secrets Act — and the Uniform Trade Secrets Act adopted by 49 U.S. states. This next step is a critical adjunct to the new Criminal Code protections and would address Canada’s continued lack of adequate enforcement while providing harmonization with the U.S. in the protection of these key intellectual property rights in a digital economy.

**Slow Examination of Trademark Applications**

IPO remains concerned about the slow examination of trademark applications by the Canadian Intellectual Property Office (“CIPO”). It appears, based on available statistics, that CIPO is the slowest national office in the world when it comes to the examination of trademark applications.

CIPO’s primary strategy for dealing with the backlog has been to accelerate the examination of applications that use only the descriptions of goods and services that are in CIPO’s Pre-approved List of Goods and Services. We note, however, that CIPO’s preferential treatment of such applications has come at the expense of applications not solely using the Pre-approved List of Goods and Services. For example, in the past 12 months, CIPO has only examined two months’ worth of such applications. The situation is now so dire that CIPO is reporting, as of November 25, 2022, that it is only examining applications not using solely the Pre-approved List that were filed on March 8, 2019.

In other words, a trademark owner who filed a Canadian trademark application in March 2019 was only having its application examined by the CIPO for the first time more than 44 months later. Despite this worsening backlog, the CIPO has not presented a viable plan for bringing its timeline for examination within international norms.

**Language Requirements**

Recent changes made by the province of Québec to its language laws in Bill 96 will, when fully implemented, make it considerably more difficult for trademark owners to use English-only versions of their trademarks in the province.

IPO is concerned in particular about the provisions of Bill 96 which, when they take effect on June 1, 2025, will mandate that a trademark can be displayed on a product solely in a language other than French only if:

- the trademark is registered with the Canadian Intellectual Property Office (“CIPO”); and
- no French version of the mark has been registered as a trademark.

In addition to its concerns about these restrictions on the right of a trademark owner to display their mark in the language of their choice, IPO is also concerned that CIPO’s slow pace of

examination will make it practically impossible for a trademark owner who wishes to take advantage of the above exception to obtain a registration for a non-French version of their mark before the law takes effect on June 1, 2025.

**Other Concerns**

IPO believes that the Government of Canada should be more progressive in its approach by amending its laws to better define their boundaries in order to create greater business certainty. For example, Canada’s policy of allowing transfer of prior user rights to third parties establishes an unstable foundation for reliable patent protection.\(^\text{53}\) Another example is Canada’s file wrapper estoppel rules,\(^\text{54}\) which have been unfairly applied retroactively and created a significant disruption in existing patent proceedings. Canada’s data protection practices are also a concern due to court challenges calling into question the scope of protection provided for test data. Notably, when the Government of Canada has sought public comments on new proposals, the deadlines for comment are sometimes extremely short and, in IPO’s view, do not allow sufficient time for a thoughtful perspective to be provided. Patent owners would like Canada to take steps to provide stronger protections for innovation.

**CHILE**

**Pending Fármacos-II Bill**

Chile, which has developed a leading health and innovation ecosystem, is at risk of reversing progress, developing anti-intellectual property laws, and suggesting unhelpful modifications to its regulatory affairs process. Amendments proposed by the Health Committee of the Chamber of Deputies under the Fármacos II bill remain pending and would expand compulsory licenses, restrict use of brand names for medicines, and suggest modifications to regulatory affairs for bioequivalent drugs and in the process for regulatory registration of drugs. These developments risk Chile’s leading position and threaten continued innovation in Chile.

More specifically, IPO is concerned about the doctor’s obligation to prescribe medications exclusively by their International Common Name in the prescription, not designating the trademark, and that the medicine packaging must include the name of the product in question, according to its international common name, in letters of a size that, as a whole, use at least one third of one of its main faces. Medicines may only have a “fantasy” name on the container, in a size that, as a whole, does not exceed one fifth of the size used for the international common name. Requiring qualified professionals to prescribe drugs using the International Common Name of the drug will then lead the pharmacy to dispense any version of the drug, including bioequivalent drugs, without any input or benefit of the judgment of the qualified professional.

These measures would also excessively broaden the scope of compulsory licenses,

---


incorporating vague and discretionary elements such as the “shortage” or the “economic inaccessibility” of pharmaceutical products. They are not consistent with internal legislation or with the international treaties that Chile has signed, which promote the protection of these rights in order to encourage innovation.

CHINA

**Phase I Economic and Trade Agreement**

The United States and China entered into Phase I of the Economic and Trade Agreement on January 15, 2020, which promised improvements in intellectual property and tech transfer in China. IPO notes, in particular, that provisions in Chapter 1 called for needed improvements in trade secret protection, measures against bad faith trademarks, and the protection of patents relating to pharmaceuticals. IPO has monitored the implementation of the agreement and continues to do so.

**Trade Secrets: Positive Developments and the Need to Upgrade**

Trade secret law in China is fragmented, with protection provided under several different legal and administrative provisions, including those involving anti-unfair competition, contract, and labor laws, among others. In these differing regimes, there have been a few developments.

For example, China amended its Anti-Unfair Competition Law in 2019. The State Administration for Market Regulation then published Draft Rules on Trade Secret Protection for public comments in 2020 and published a revised draft of the Anti-Unfair Competition Law in November 2022, but to our knowledge no final rules have been put in place. The Supreme People’s Court and Supreme People’s Procurate also jointly published Interpretations on Several Issues Concerning the Application of Law in the Trial of Civil Cases of Trade Secret Infringement Disputes. These amendments, new rules, and judicial interpretations appear to indicate that China desires stronger enforcement against trade secret misappropriation. IPO hopes that this continues a trend of expanded enforcement of trade secret rights in China.

---

55 See Anti-Unfair Competition Law (as amended April 2019), http://www.npc.gov.cn/npc/c30834/201905/9a37c6f150c4be6a549d526fd586122.shtml.
Although recent developments are promising, trade secret owners still face significant challenges protecting their confidential information. High evidentiary burdens, limited discovery, and multiple damages issues are considerable obstacles. Not only is the act of seeking relief difficult, but it can require waiting until additional damage transpires. Under criminal law, theft is determined by the consequences of the loss, as opposed to the act of misappropriation. Even if a trade secret owner knows a theft has taken place, a criminal investigation cannot begin until a significant and possibly irreversible injury has taken place.

The way a misappropriator uses a trade secret can also affect the ability to obtain relief under civil law. For example, where the misappropriator benefits from a trade secret by virtue of accelerated development rather than actual profits or other unjust gains, such a concept is not formally recognized in the determination of damages to the trade secret owner. The requirements for many businesses to submit technical and functional features of their products, as well as confidential test data, as a condition for access to the Chinese market present further challenges for protecting confidential business information. Further, China’s Patent Law gives local and provincial patent administration and enforcement IP offices new powers to investigate patent infringement cases, including giving them broad authority to inspect the sites where the alleged infringement takes place and to review and copy relevant documents. Our members are concerned with the significant risk of trade secret disclosure that could result from administrative investigations. Absent proper safeguards, such administrative enforcement of patents could result in disclosure of confidential information. The consequences of such disclosures to government agencies can be particularly harmful because receiving agencies might be willing to provide such confidential information to the public on request. In some cases, the information provided is reviewed by expert panels that include employees of local businesses and institutions that might benefit financially from having access to another company’s trade secrets. Although, at the 2014 Joint Commission on Commerce and Trade, China promised to hold government officials with access to confidential business information accountable and otherwise shield the details from public disclosure, the impact of any changes has yet to be felt.

In summary, in China, our members face high burdens of proof, limited discovery, and damages issues when seeking to enforce their trade secrets. While preliminary injunctions in the form of conduct preservations are more recently being granted in trade secret actions, such relief remains uncommon and unpredictable particularly in view of the high threshold of proof, and thus a trade secret owner usually must wait until a significant and possibly irreversible injury has taken place before seeking relief. Our members also face requirements to submit confidential details to government agencies. Although IPO is encouraged with recent upgrades, such as the expanded availability of injunctive relief in China’s amended civil procedure framework, more needs to be done to protect trade secrets. IPO is encouraged by Section B (Articles 1.3-1.9) of the Phase I Economic and Trade Agreement between the U.S. and China, which when fully implemented, will substantially improve trade secret protection in China.

---

58 A threshold of 300,000 RMB must be met. See the Interpretation on Several Issues Concerning the Specific Application of Law in Handling Criminal Cases of Infringement of Intellectual Property Rights, released jointly by the Supreme People’s Court and Supreme People’s Procuratorate on September 13, 2020.

59 The Patent Law of the People’s Republic of China effective 1 June 2021, Article 69.

**China Lacks a Meaningful Grace Period for Design Applications**

While the recently updated Patent Law of China makes a number of improvements to design patent law, including provision for partial designs and a longer term of protection, China is one of the few modern countries not to have a meaningful grace period during which a design owner can file a design application after disclosing the design publicly anywhere in the world.\(^61\) This is one of the reasons deterring foreign applicants from obtaining design patents in China, as reflected by the numbers of grant of design patents.\(^62\) Unsophisticated designers may not appreciate the need to file a design application before disclosing their design, at which point protection will be unavailable in China. Further, grace periods — like those adopted in the U.S., Europe, Japan, South Korea, Canada, and Australia — provide applicants the time and flexibility to consider the need for protection and to prepare quality applications. China should be encouraged to adopt a generally applicable grace period of at least 6 months, and preferably 1 year.

**Implementation Guidelines are Needed to Give Effect to the Improvements in the Amendments Regarding Industrial Designs**

We commend China on recent improvements in the patent law amendments with respect to the protection of industrial designs. However, without implementation details in effect, no guidance or standards exist for how these changes should be carried out. As such, there is uncertainty about how these changes will be implemented. We encourage China to swiftly move forward with finalizing its implementation guidelines to create more certainty and consistent practices.

**Anti-Suit Injunctions**

Beginning in August 2020, Chinese courts have issued anti-suit injunctions that have arguably tipped the scales in favor of domestic businesses, while raising due process and transparency issues. In the face of a specific request by the European Union, which filed an Article 63.3 request at the WTO on July 6, 2021 requesting further information on four standard essential patent (SEP) cases in China, China rebuffed the EU’s request and failed to make those decisions public.\(^63\) Since then, Japan, Canada, and the U.S. have joined in the Art. 63.3 Consultation process. IPO remains optimistic that these efforts will yield substantial improvements in due process and transparency. Most recently, the EU requested that a panel be set up by the Dispute Settlement Body to examine the matter.

---

\(^{61}\) There are grace periods for disclosures for the benefit of the public interest. See the Patent Law of China, effective June 1, 2021, Article 24.

\(^{62}\) In 2021, design patent grants from the CNIPA were: 17,061 to foreigners, 768,460 to domestic entities. See [https://english.cnipa.gov.cn/col/col3050/index.html](https://english.cnipa.gov.cn/col/col3050/index.html).

\(^{63}\) See European Union, Request for Information Pursuant to Article 63.3 of the TRIPS Agreement (July 6, 2021), [https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=t:/IP/C/W682.docx&Open=True](https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=t:/IP/C/W682.docx&Open=True); see also, P.R. China, Response to the European Union's Request for Information Pursuant to Article 63.3 of the TRIPS Agreement (Sep. 7, 2021), [https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W683.pdf&Open=True](https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W683.pdf&Open=True).
Challenges Created by Chinese Trademark Law

Several amendments to China’s trademark law became effective on November 1, 2019. These amendments, together with those made in 2013, improved the law, such as with the addition of a good-faith requirement when applying for new marks and the rejection of bad faith trademark registrations without an intent to use. Yet, brand owners still face substantial challenges. For example, failed oppositions result in immediate registration of challenged marks in the absence of a right to appeal, forcing brand owners to initiate separate invalidation proceedings before the Trademark Review and Adjudication Board. As the brand owner waits, a bad faith registrant can build up years of use, improving its chances to use the mark permanently under Chinese jurisprudence. Bad faith registrants might even be able to take enforcement action against a brand owner’s use of its own trademark.

The 2014 PRC Trademark Law dropped the Opposition Review, depriving both parties of their rights of action. As the success rate of opposition in China is very low, the removal of Opposition Review from the PRC trademark framework can only make things worse. Once bad faith registrants get their registration certificates, the brand owners will bear a heavy burden to invalidate them, not to mention the infringement risks caused by the registration if the non-registrant brand owner continues using their unregistered mark. Even if the invalidation action goes well, the process takes about one year, and the bad faith registrant might continue to appeal to the courts at three levels, which takes at least an additional three years, delaying resolution of the dispute, to the detriment of the brand owner.

IPO also notes that, in late 2015, the Chinese Trademark Office began invoking the Article 7 good-faith requirement to invalidate abusive trademark registrations. On November 22, 2021, the CNIPA revised its trademark examination guidelines, defining 10 actions of bad faith trademark application behavior with no purpose of use. Factors to consider include the number of trademarks filed by the applicant and the transaction situation (targeting professional squatters), the business nature of applicant, and similarity to famous trademarks.

Although this represents needed progress, China should be encouraged to continue to rein in trademark abuse. Bad faith trademark filings include “trademark squatters” who file trademark applications and obtain registrations on the internationally established trademarks of brand owners, either to sell them back to the brand owner or to confuse the public and consumers. Establishing bad faith in these circumstances is too difficult and the standard for establishing the brand owner’s trademark as “well known” is excessively high (even beyond famous), particularly where the bad faith trademark filing is made before launch of the legitimate branded product in China. Moreover, to avoid abuse, IPO believes that China should look to evidence outside China of the fame and whether a trademark is well known, rather than limiting such inquiry to fame within China. IPO looks forward to seeing more rejection of bad faith trademark applications under the newly amended Article 4, and to implementation of Section H (Article 1.24) of the Phase I Economic and Trade Agreement between the U.S. and China.

---

64 See https://www.cnipa.gov.cn/art/2021/11/22/art_74_171575.html.
IPO notes the draft amendments to China’s trademark law released January 13, 2023,\textsuperscript{65} which IPO is currently analyzing to determine both to what extent the above issues are addressed and whether it raises additional issues worthy of note.

**Incomplete Delinking of Indigenous Innovation from Government Procurement**

Since 2011, China has committed to delink its innovation policies from government procurement preferences. Much progress has been made since then, with several provinces and sub-provincial units issuing notices to comply with a State Council notice requiring the policy change. It is clear, however, that a relationship between indigenous innovation and government procurement still exists today. There have been several examples, such as the catalog of indigenous innovation products established by the Economic and Information Technology Bureau of Yinzhou District or the budget notice from Nanxian County, Hunan stipulating the same preferences. Therefore, although IPO is encouraged by China’s renewed commitment at the 27\textsuperscript{th} JCCT to build on the country’s 2011 commitment, the U.S. should encourage implementation to move at a more rapid pace.\textsuperscript{66}

Along similar lines, IPO is concerned there are indications that China might be establishing sovereign patent funds to provide an advantage to Chinese companies in the market.

**Forced Technology Transfer**

The 2020 Foreign Investment Law has provisions that, if effective, could constitute substantial progress in dismantling policies, laws, regulations, and practices that force technology transfer. Article 22 of the law provides, among other things, that “administrative organs and their employees must not force the transfer of technology through administrative measures.” The concern is that this language might prove open to loopholes that would prevent it being fully effective. For example, if a transfer is mandated other than “through administrative measures” it might not be considered a violation of the law.

In addition, there are many other laws, regulations, and practices outside the Foreign Investment Law that would serve to undermine the restriction against forced technology transfer. For example, joint venture requirements and data localization requirements for internet and cloud companies, as well as biopharmaceutical companies conducting research in China, mean that foreign companies are, as a practical matter, forced to hand over their IP to local PRC companies in order to participate in the Chinese market. Moreover, the Fourth Amendment to the Patent Act, which was effective June 1, 2021, increases the power of administrative agencies to investigate patent infringement which may involve seizing confidential information including trade secrets, which might result in the disclosure of such trade secrets to others, including competitors. Regulatory laws such as environmental, pharmaceutical, and medical device approval requirements can also result in concerning disclosures of confidential information, particularly where information is sought more broadly

\textsuperscript{65} https://www.cnipa.gov.cn/art/2023/1/13/art_75_181410.html
than reasonably necessary to accomplish regulatory review or where the regulatory agencies share submitted information with competitors (such as technical experts employed by or affiliated with competitors) or share submitted information with later regulatory applicants (or use it on their behalf). IPO looks forward to further developments in the implementation of Articles 1.9, 2.2 and 2.3 of the Phase I Economic and Trade Agreement, which require improvements in the protection of trade secrets and confidential business information from unauthorized disclosure by government authorities and prohibit forced technology transfer through administrative and licensing requirements, or through requirements for acquisitions, joint ventures, and other transactions.

**Patent Enforcement and the Amendment to Chinese Patent Law**

Language in China’s 4th Amendment to its Patent Law\(^\text{67}\) raises concerns that, in some instances, valid patent rights might not be enforced. Article 20 of the Patent Law creates uncertainty by its ambiguity. It requires those who apply for and exercise patent rights to act in good faith and not misuse patents to “damage public interests or others’ legal rights.”\(^\text{68}\) While the draft Amendments to the Implementation Rules of the Patent Law include Article 43-1 which gives a little more detail, the draft appears not to have been implemented yet, and there continues to be a lack of detail to fully explain this principle or guide the courts and administrative agencies that are tasked with enforcing it.

Under the law, there is some risk and uncertainty that certain aggressive and bad-faith patenting practices may be deemed patent misuse. Without a clear definition of what practices may amount to patent misuses that damage the public interest or others’ legal rights, this article may create some uncertainty for patent owners who seek to legally exploit and enforce their patents. This also raises questions regarding consistency with TRIPS Article 30, which provides that the exceptions to the exclusive rights conferred by a patent should not unreasonably conflict with a normal exploitation of the patent and unreasonably prejudice the legitimate interests of the patent owner, considering the legitimate interests of third parties. China’s National Intellectual Property Administration (CNIPA) has extensively addressed what it has determined to be misuse since 2021, and the current targets are all Chinese entities.\(^\text{69}\) It remains a concern whether such efforts would extend to foreign entities.

Moreover, the high and growing volume of utility models in China,\(^\text{70}\) combined with the lack of examination with respect to patentability, creates substantial uncertainty for U.S. companies in the Chinese market. Although CNIPA has acknowledged the extent of the problem by rejecting some utility model applications that are “obviously unpatentable,” more safeguards are needed to ensure these patents are not inappropriately used against innovative companies. One such

---


\(^2\) Id. at Art. 20.


measure would be to automatically stay infringement proceedings until timely invalidation requests have been resolved. Another measure would be to require that utility models only be granted after obtaining a patentability evaluation report, which would be published with the utility model at grant.

The 4th Amendment to the Patent Law continues to expand administrative enforcement of patent rights. It gives hundreds of inexperienced local and provincial patent administration and enforcement offices new powers to investigate and inspect, to grant injunctive relief, and to impose fines and penalties for patent infringement. One of the effects of the 4th Amendment to the Patent Law is to allow entities or individuals to assert their rights before local and administrative officials, who might not be technologically and legally qualified, without clear guidance tying any award to the value of the patent. This change fragments enforcement, interpretations, and procedures regarding patent laws and the related rights, making enforcement in China less predictable and extremely difficult to navigate. In addition, the 4th Amendment to the Patent Law specifies that certain patent infringement cases with nationwide influence may be handled by CNIPA, and two such cases had already been accepted by the CNIPA in November 2021.\textsuperscript{71} The first decision has been issued on July 27, 2022, in a case with a foreign pharmaceutical company patentee suing a Chinese company, in favor of the foreign patentee.\textsuperscript{72} It appears from this case that once the infringement occurred in multiple provinces/municipal cities, CNIPA had the jurisdiction. However, there is still unclear guidance on the criteria for classifying cases as significant cases. While some classes of cases are specified as possibly significant cases, whether a particular case falls within one of those classes is uncertain because of the lack of detail.

To be more effective, China’s patent system should allow for appropriate recourse to civil litigation for patent infringement to the exclusion of administrative enforcement remedies, which can be political, unprofessional, and discriminatory. This would help rights-holders demonstrate the value of their patents or other IP, by addressing, among other issues, the problem of insufficiently examined rights by adjudication before more experienced, technically trained, competent, and less political courts.

One positive development is the revision to the previous set of Patent Examination Guidelines, implemented by CNIPA on January 15, 2021,\textsuperscript{73} whereby supplementary data could be conditionally accepted to prove both sufficient disclosure and inventive step for technical effects already cited in the specification, even if the applications as filed do not provide any data. IPO is encouraged that these changes may foster timely filing of applications for new drugs by allowing applicants to later submit additional information consistent with the drug development process. Whether the amendments will make a substantial impact in the long term, however, is uncertain because in practice the admission of supplementary data is currently examiner dependent, and appears to be generally not welcomed. IPO also notes

\textsuperscript{71} See https://www.cnipa.gov.cn/art/2021/11/15/art_53_171429.html.

\textsuperscript{72} See https://www.linkedin.com/pulse/1st-cnipa-important-patent-infringement-decision-toby-mak/?trackingId=WmpzpTAPS$Sr9lZro8JvA%3D%3D, with the decision published briefly on the internet and the removed by the CNIPA.

\textsuperscript{73} Amendment to the Guidelines of Patent Examination According to CNIPA Announcement No. 391 (effective January 15, 2021).
changes in sections 4.2 and 4.3.1 harmonizing Chinese patent practice with U.S. patent practice in allowing invalidity petitioners to submit new evidence of invalidity when patent owners seek to amend their claims during the invalidity proceeding.

IPO is glad to see CNIPA’s effort to improve patent quality and the examination process with respect to invention patent applications containing algorithm or business rule and method features, as indicated by the Draft Revised Patent Examination Guidelines, published on August 3, 2021. However, this amendment introduces confusion as to patentable subject matter for computer programs, and further clarity is needed on whether an invention includes a “technical means.” IPO is concerned about these changes, which are being made at a relatively low level (via Examination Guidelines), substantively impacting the patentability standards for computer programs and causing broader confusion on how to apply patentability standards, without the changes being coherently addressed in higher-order changes to the laws or regulations.

IPO notes that, at the direction of the Supreme People's Court, the Beijing IP Court has embarked upon an initiative to use guiding cases in deciding new IP cases, including establishing a database of “Guiding Cases” and a research organization for identifying guiding cases to add to the database. Such efforts reveal a desire on the part of China’s judiciary to help bring transparency and predictability to enforcement of IP rights in China. IPO believes transparency and predictability in IP enforcement in China will be improved if a system of guiding cases can be effectively spread among IP courts.

A centralized tribunal for hearing appeals in IP cases – the Supreme Peoples’ Court Intellectual Property Court – began operating on January 1, 2019. By the end of 2019 the Court reported that it had closed 1433 cases, but only about 20-30 had been published. By the end of 2020 the Court closed an additional 2787 cases, of which 55 Guiding Cases have been published, but the number of any additional published cases was not readily available. The establishment of the IP Court of the Supreme Peoples’ Court, and the publication of guiding cases, may bring predictability to enforcement of IP rights in China, but the relatively few decisions published to date and/or the lack of disclosure of the number of published cases raises concerns about the transparency of such enforcement.

Judicial transparency is critical to ensure fairness to parties and consistent case law development. Lack of judicial transparency continues to pose challenges for parties using the Chinese court system. In 2014, China mandated public access to all judicial decisions via a database called China Judgments Online. Although this mandate increased the availability of judicial decisions, courts in China are not consistently publishing decisions. Indeed, observers have concluded that Chinese courts appear to publish only around half of their patent

---

judgments.\textsuperscript{77} Even in the face of a specific request by the European Union, which, as previously mentioned, filed an Article 63.3 request at the WTO on July 6, 2021 requesting further information on four SEP cases in China, China rebuffed the EU’s request and failed to make those decisions public.\textsuperscript{78} Additionally, some parties have observed delays of one year or more from the decision to publication. IPO believes that China should implement measures to ensure that all courts comply with the mandate to publish decisions in a timely manner.

Additionally, unlike in the U.S., courts in China are not required to publish intermediate decisions, such as decisions on preliminary injunction requests. There is also no requirement to publish administrative patent enforcement decisions. To improve transparency during all stages of IP adjudication, IPO recommends that China implement a rule requiring publication of intermediate and patent enforcement decisions in a searchable database.

\textit{Potential Negative Impact of Laws and Regulations Regarding Service Inventions}

Article 15 of the Patent Law lists specific examples of incentive mechanisms for employers to share innovation profit with service inventors. IPO believes that the list of incentive mechanisms is unnecessary and might cause confusion.\textsuperscript{79} Article 15 already required an employer entity to give the inventor or designer (of a service invention) a reasonable amount of remuneration (but without specifying details). IPO is concerned that the listed examples of incentive mechanisms in Article 15 could be misinterpreted as requiring share-based awards as the only acceptable type of remuneration, and thereby as limiting the employer’s freedom in remunerating its employees. IPO would like to see clarification that the obligation under Article 15 of the Patent Law to give inventors remuneration shall be considered satisfied by compliance with an employer’s invention remuneration rules, regulations, plan, policy, or compliance with an agreement between employer and inventor regarding inventor remuneration, preferably in the final Implementing Regulations of the Patent Law. IPO notes that currently the Draft Amendments to the Implementing Regulations (Published for Comments November 27, 2020) acknowledges in Article 76-1 that employers and employees may agree to reward and remuneration as required under Article 15.

\textit{Unique Challenges to Pharmaceutical Protection}

Our members welcome the patent term extension for pharmaceutical products in Article 42 of the 4\textsuperscript{th} Amendment to the Patent Law. The National Medical Products Administration (NMPA) and CNIPA published Measures for the Implementation of Early Resolution Mechanisms for


\textsuperscript{78} See European Union, Request for Information Pursuant to Article 63.3 of the TRIPS Agreement (July 6, 2021), \url{https://docs.wto.org/dol2e/EN/View/SS/MN/2012/W82.DOCX&Open=True}; see also, P.R. China, Response to the European Union’s Request for Information Pursuant to Article 63.3 of the TRIPS Agreement (Sep. 7, 2021), \url{https://docs.wto.org/dol2e/EN/View/SS/MN/2012/W683.PDF&Open=True}.

\textsuperscript{79} Article 15, the 4\textsuperscript{th} Amendment to Patent Law of the People’s Republic of China, published on November 19, 2020, effective June 1, 2021, \url{http://www.npc.gov.cn/npc/c30834/202011/82354d98e70947e09dbc5e4eeb78bdf3.shtml}.
Drug Patent Disputes (“Measures”) on July 4, 2021. The Supreme People’s Court also published the Provisions on Several Issues Concerning the Application of Law in the Trial of Patent Civil Cases Involving Drug Marketing Review and Approval (“Provisions”) on July 5, 2021. As of October 2021, twelve drug patent linkage complaints had been accepted by the CNIPA, while the Beijing IP Court had accepted one.80

The patent linkage provisions are new for China. A fair and effective linkage system for China will not only need to balance the interests of generics and innovators, but also will need consistency between the courts and the range of concerned administrative agencies.

Synchronous reforms to the relevant laws and regulations are necessary to enable stakeholders to consider the proposed scheme fully and holistically. Furthermore, rules and judicial interpretations should be harmonized with higher level laws and regulations.

Article 76 of the Patent Law is directed to drug marketing applications. IPO would like to see a broad definition of “drug” (e.g., to include both chemicals and biologics) to reflect the current state of the art in the field. Similarly, the applicable patents should broadly include those directed to chemical compounds, chemical compositions, pharmaceutical composition or formulation, method of manufacturing of the active ingredient, specific medical use, etc. The current version of the Measures and Provisions needs to be revised to reflect the broad definition of “drug” and the wide range of patents. For example, the Measures limit only sequence structure and medical use patents that can be registered for biologics. For chemicals, patents covering intermediates, metabolites, crystal forms, methods of manufacturing and testing methods are not considered as relevant patents under the patent linkage system.

IPO is concerned about the absence of a time limit for the court to issue a decision in the Measures. The current version of the NMPA/CNIPA’s Measures has a 9-month time limit for litigation to conclude, which the Provisions do not. Failure to conclude the litigation within 9 months allows the NMPA to end the moratorium on approval. As the NMPA does not suspend evaluation during the moratorium, it is possible that the NMPA could issue marketing approval before the litigation concludes. The NMPA will not revoke marketing approval even if the Beijing IP Court rules against the generic manufacturer, rendering the patent linkage litigation moot. Furthermore, the 9-month time limit applies only to small molecules and not biologics.

IPO is also concerned about the lack of moratorium on approval when a generic drug applicant only challenges that an in-force patent should be declared invalid under the so-called type 4.1 declaration. This effectively allows the NMPA to process the approval of the generic drug immediately even if the generic drug applicant does not file any invalidation challenge after filing the type 4.1 declaration.

With respect to patent examination, China recently changed its patent examination guidelines to allow patent applicants to file additional biological data after filing their applications, and confirmed that its patent examination guidelines would no longer be applied retroactively. This

80 See https://www.cnipa.gov.cn/art/2021/10/29/art_53_171065.html and https://mp.weixin.qq.com/s/0PNtsF0XBuwxULgYqnV-Uw.
is a welcome step. Concerns remain, however, that CNIPA appears to be imposing new and unfair or inappropriate limitations and interpretations of the new amendment, including at the appeal (Patent Reexamination and Invalidation Department) level on the use of post-filing data to satisfy inventive step requirements.

In a positive development, China has implemented plans to improve drug safety and severely crack down on the production and sale of counterfeit medicines. The production, distribution, and sale of counterfeit medicines and unregulated active pharmaceutical ingredients, however, remain rampant in China and continue to pose a threat to China and its trading partners.

**Requirements for Foreigners to Hire Local Patent Agencies**

In China, domestic applicants may file their patent applications directly with CNIPA. Foreign applicants who want to own their patent assets must appoint a patent agency to represent them before CNIPA.\(^8^{1}\) Hiring a third party, however, can increase both expense and risk that confidential information is lost in the process. For companies with significant operations in foreign countries, it is not uncommon to have in-house operations that manage the patent application process including filing applications. This is not possible under China’s current Patent Law.

Although companies can avoid filing through a third party by establishing a Chinese business unit, relevant patent applications must be assigned to a Chinese entity. This complicates patent ownership by splitting up a potential family of assets among several entities, can disqualify the applicant from receiving incentives in other countries, and might not even be allowed based on contractual obligations. U.S. companies should be allowed to file patent applications in their own names, as long as subsequent prosecution is handled by an in-house or outside attorney or agent qualified by CNIPA.

**Genetic Resources and Traditional Knowledge**

Article 26 of the Patent Law requires patent applicants to indicate the “direct source” and the “original source” of genetic resources if the completion of the claimed invention relies on access to genetic resources. These provisions are intended to implement provisions of the Convention on Biological Diversity (CBD) relating to access to genetic resources and equitable sharing of benefits from utilization of these resources. These special disclosure requirements are ambiguous and, as a result, impose unreasonable burdens on patent applicants, subjecting valuable patent rights to great uncertainty. Thus, IPO believes that these requirements should be deleted.

China’s human genetic resource (HGR) regulations, which came into effect on July 1, 2019, prohibit human sample collection by foreign parties and restrict the use, analysis and transfer of such samples and related data except in the context of an approved collaboration with Chinese parties, such as medical institutions or enterprises with no foreign investment. The regulations also contain provisions regarding mandatory IP sharing that are inconsistent with Chapter 2 of

---

the Trade Agreement, which provides that any transfer of technology as part of securing marketing approval for innovative medicines occurs on voluntary, market-based terms.

COLOMBIA

Compulsory Licenses

In July 2022, the Ministry of Health (MoH) issued recommendations regarding procedures for declaring public interest for compulsory license purposes, particularly related to a pending compulsory license request for Hepatitis C drugs. The MoH specifically recommended that Public Interest should not be declared in this case. Additionally, in response to a petition from several NGOs, related to public access to Nirmatrelvir for COVID treatment, wherein it was requested that TRIPS flexibilities be used for manufacturing, importing and distributing this drug in Colombia, the Colombian government stressed in May 2022 that the existing strategic pandemic management committee would advise on the need to make Nirmatrelvir available to the public. However, the Health Ministry concluded that at this moment it is unnecessary to initiate Public Interest Declaratory procedures.

IPO is concerned about suggestions that the New National Development plan, which is currently under development, should encourage compulsory licensing.

Industrial Designs

In September 2022, the Superintendency of Industry and Commerce (CPO) issued modifying directives for submitting Industrial Design applications (ID). According to the new directives, graphical user interfaces (GUI) must be presented without being associated to a device or screen. In turn, animated designs should include numerated drawings showing the sequence that allows understanding the movement of the animation. This simplifies enormously ID prosecution, since it will be no longer necessary to include several independent drawings.

Genetic Resources and Traditional Knowledge

Andean Decision 486, which applies in Colombia, requires that patent applications include requirements relating to the acquisition or use of genetic resources if the relevant inventions “were obtained or developed from” genetic resources originating in one of the Andean Community countries (Bolivia, Peru, Ecuador or Colombia). It similarly applies to inventions derived from traditional knowledge originating in the Andean Community. For the same reasons articulated in the genetic resources and traditional knowledge section above (within “Highlighting Broad Concerns),” IPO believes these requirements should be eliminated.
INDIA

Economic Advisory Council to the Prime Minister of India Submitted its Report on “Why India Needs to Urgently Invest in its Patent Ecosystem?”

In August 2022, the Economic Advisory Council to the Prime Minister of India submitted its Report on “Why India Needs to Urgently Invest in its Patent Ecosystem?” The Report flagged that despite having the average timespan of only 4.8 months for issuing the first office action during substantive examination of patent applications (which is one of the shortest in the world), the average timespan for final disposal of patent applications in India is still about 58 months. The Report appears to identify several reasons for the delay in disposal of patent applications and has made recommendations to address these.

Lack of fixed timeline for filing pre-grant oppositions against patent applications: As of present, a pre-grant opposition against a patent application can be filed by ‘any person’ at any time after the application has been published and before grant. Staggered oppositions result in significant delays. The Report suggests that the time-period for pre-grant opposition be limited to 6 months from the date of publication, as is the case in the U.S.

Cumbersome compliance requirements for the Applicants to submit details regarding processing of foreign patent applications (under Form-3), particularly in relation to PCT Applications: The Report suggest that such information is readily available online through WIPO CASE, where India is a member. The Report recommends that the provision be suitably amended.

While the number of Examiners (responsible for issuing first office action) at the Indian Patent Office appears to be adequate, there is an acute shortage of Controllers (responsible for further examination, hearings, and disposal of patent applications). The Report mentions that there are only 247 Controllers in India. The Report relied upon recommendations of Parliamentary Committee’s on “Review of the Intellectual Property Rights Regime in India” to suggest urgent increase in manpower, particularly Controllers.

In addition to the above, the Report notably recommended the introduction of utility model patents in India. The Report suggested new legislation for the utility model patent system.

83 Id., at pages 11 and 13.
84 Id., at page 15.
85 Id., at pages 9, 10, and 12.
86 Id., at page 15.
Parliamentary Committee’s Report No. 169 on Actions Taken by Government as per the Recommendations in Report No. 161 on “Review of the Intellectual Property Rights Regime in India”

In July 2021, the Parliamentary Standing Committee on Commerce presented a Report (No. 161) entitled “Review of the Intellectual Property Rights Regime in India,”87 before both houses of the Parliament. The Report made 82 recommendations towards strengthening the IPR regime of India. Observations and recommendation include (i) the need for an immediate review of the IPR Policy 2016 by the Department for Promotion of Industry and Internal Trade;88 (ii) enacting separate legislation or framework for protection of trade secrets;89 (iii) re-establishing, instead of abolishing, the Intellectual Property Appellate Board (IPAB) with greater autonomy and reforms;90 (iv) establishment of dedicated IP benches at High Courts;91 (v) exploring and enabling PPH programs with other countries;92 (vi) including a mechanism to safeguard against the arbitrary exercise of power by the Controller in declining patents;93 and (vii) enacting specific legislation to curb counterfeiting and piracy.94

On April 6, 2022, the Parliamentary Standing Committee presented a Report (No. 169) before both houses of the Parliament on “Action Taken by Government on the Recommendations/Observations of the Committee contained in its 161st Report on 'Review of the Intellectual Property Rights Regime in India.'”95 As per the Report, it is recorded that out of 82 recommendations: (a) 48 have been accepted by the government; (b) 21 will not be pursued in light of government response; (c) 12 responses received from government are not accepted by Committee; and (d) one response not received from government. IPO is encouraged by the positive response from the government on the recommendations of separate legislation or framework for protection of trade secrets96 and that a working group has been formed for a new PPH program with Denmark.97 IPO, however, notes that the government’s response is vague and generic in respect of most of the key issues, such as setting up of specialised IP Benches and IP Divisions in the High Courts,98 resolution of the patentability criteria and disqualification of incremental inventions under Section 3(d) as flagged by the USTR Report,99 arbitrary exercise of power by Controller in declining patents,100 etc. The Report made some

88 Id., at page 96.
89 Id., at page 111.
90 Id., at page 101.
91 Id., at page 114.
92 Id., at page 102.
93 Id., at page 104.
94 Id., at page 100.
96 Id., at page 32.
97 Id., at page 12.
98 Id., at page 39.
99 Id., at page 14.
100 Id., at page 13.
further recommendations, including making amendments to legislations and regulations to enable protection of AI related inventions and for establishment of IP Divisions in all High Courts. These are also summarised the official Press Release.

**National IPR Policy**

Overall, India’s IPR Policy (Policy) unveiled in May 2016 still provides a valuable roadmap for realizing the potential of India’s creativity and recognizes the central role IP plays in this regard. The Policy lays down seven objectives with action points for each objective to stimulate a dynamic, vibrant, and balanced IP rights system in India. Among other positive recommendations, IPO is encouraged by the Policy’s recommendation to further study the protection of trade secrets. As discussed below, improving India’s trade secret regime is critical to ensuring a level playing field for non-Indian innovators.

Although much of the Policy is still being implemented, some recommendations should be closely monitored. For example, item 2.16 in the Policy proposes statutory incentives, like tax benefits linked to IP creation, for the entire value chain from IP creation to commercialization. Although incentivizing the pursuit of IP protection and its use is a laudable objective, caution should be exercised to prevent frivolous filings being made just to benefit from this initiative. Regarding the tax benefits, clarity is needed on how to value IP creation. Further items whose implementation will be interesting to observe include: 3.9 for guidelines on technology transfer, know-how and licensing of SEPs; 4.15 for India’s accession to Hague System; 4.16.1 on timelines for grant of registrations and disposal of opposition matters; 6.8 for strengthening protection mechanisms for protection of IP rights; and 6.10 for effective adjudication of IP disputes.

Some of the Policy objectives are implemented through different vehicles. Item 4.13 of the Policy has been implemented, wherein a Cell for IPR Promotion and Management (CIPAM) has been set up with the guidance of the Department for Promotion of Industry and Internal Trade (DPIIT). CIPAM facilitates programs and initiatives for IPR awareness, promotion, creation and commercialization of IP assets as per the Policy. CIPAM prepared and released “Draft Model Guidelines on Implementation of IPR Policy for Academic Institutions” with the objective to frame a uniform IP Policy for licensing and commercialization of IP rights for academic institutions on national level. The provisions were primarily based on the Guidelines on Developing Intellectual Property Policy for Universities and R&D Organizations, WIPO, and introduce, for the first time, an ‘incentive model’ for allocation of royalties to inventors. This is related to implementation of at least two objectives under the Policy – Generation of IPRs and Commercialization of IPRs.

---

101 *Id.*, at page 76-78.
102 Press Release, Department Related Parliamentary Standing Committee on Commerce, [https://rajayasabha.nic.in/rsnew/Committee_site/Committee_File/Press_ReleaseFile/13/159/514P_2022_4_15.pdf](https://rajayasabha.nic.in/rsnew/Committee_site/Committee_File/Press_ReleaseFile/13/159/514P_2022_4_15.pdf)
104 *Id.* at ¶ 3.8.4.
Immediately after the Policy, a *Scheme for Facilitating Startups Intellectual Property Protection* (SIPP) was launched in May 2016, which has been currently extended until March 2023. It is appreciated that the benefits of the scheme, such as concession (of up to 80%) on the official charges payable at IP Offices by start-ups and small entities have been extended to foreign companies, individuals, and education institutes as well. Also, item 4.14 has been implemented by enabling expedited examination of patent applications for at least selected applicants (such as start-ups and small entities).

Taken as a whole, the Policy includes many positive actions for improving India’s IP systems, and while there have been efforts towards implementation of several objectives to varying degrees, IPO has yet to see a sustained and organized implementation of several key objectives.

In its 2021 Report,\(^\text{106}\) the Parliamentary Committee had recommended a review of the IPR policy upon completion of 5 years. Pursuant to the government’s response towards actions undertaken, as recorded in the 2022 Report,\(^\text{107}\) a further review of the Policy is not being pursued.

The U.S. should continue to monitor the implementation of the Policy as it unfolds. IPO was pleased to learn about the bilateral Memorandum of Understanding on IP cooperation, which was signed in December 2020. IPO encourages increased IP dialogue between the two countries.

**Higher Threshold of Patentability for Pharmaceutical Inventions**

India’s Patent Act provides a threshold for patentability which appears to be higher than the one allowed under TRIPS. Section 3(d) requires enhanced efficacy for new forms of known substances in order for an invention to be eligible for patent protection. It appears that Section 3(d) is discriminatory against pharmaceutical inventions and the law makes it difficult to secure patent protection for certain types of pharmaceutical inventions and chemical compounds. In its Report,\(^\text{108}\) the Parliamentary Committee, while supporting and upholding the validity and utility of Section 3(d) under the Indian Patents Act, observed concerns raised by USTR and recommended resolution of the issue through a bilateral dialogue with the U.S. The Indian Government has not provided a specific response to the recommendation, other than that a stakeholders meeting has been conducted.\(^\text{109}\)

Further, India law does not afford the availability of post-patent filing data that could be used as evidence to support novelty and inventiveness of such new compound forms.

---

\(^{106}\) 161st Report, supra at 87, ¶ 1.12  
\(^{107}\) 169th Report, supra at 95, ¶ 2.2 – 2.6  
\(^{108}\) 161st Report, supra at 87, ¶ 12.8  
\(^{109}\) 169th Report, supra at 95, ¶ 1.35
Compulsory Licensing

It is appreciated that the Government of India took a positive and firm stand (on an Affidavit) against the plea for grant of compulsory license before the Supreme Court of India reciting that it will be “presumptuous to assume that the patent holder will not agree to more voluntary licenses.”¹¹⁰

However, the Parliamentary Committee in its Report, had recommended that “the Government should delve into the prospect of temporarily waiving patents rights and issuing Compulsory Licensing to tackle the inadequacy in availability and accessibility of Covid-19 vaccines and drugs during an emergency like situation induced by the pandemic.”¹¹¹ Also, there have been multiple directions by High courts in the public interest litigations where they have suggested the government invoke the compulsory licensing provisions. In its Response (recorded in the 169th Parliamentary Report of April 2022), while the government supported the legitimacy and validity of the compulsory licensing provisions, it has turned down the recommendation of any waiver, citing the voluntary licenses granted by the patent owners. While such provisions have not yet been invoked, the developments on this front will be interesting to monitor.

Further, Section 4.4 of India’s National Manufacturing Policy discusses the use of compulsory licensing to help domestic companies “access the latest patented green technology.”¹¹² This section creates the “Technology Acquisition and Development Fund” (TADF) to help in situations when a patent holder is unwilling to license, either at all or “at reasonable rates,” or when an invention is not being “worked” within India.¹¹³ TADF is empowered to request compulsory licensing from the Government of India.¹¹⁴

Similarly, India’s National Competition Policy requires IP owners to grant access to “essential facilities” on “agreed and nondiscriminatory terms” without reservation.¹¹⁵ The concept of essential facilities appears to cover a broad range of technologies including at least “electricity, communications, gas pipelines, railway tracks, ports, [and] IT equipment.”¹¹⁶ The unconditional application of the essential facilities doctrine to such a broad technology landscape substantially decreases the value of the underlying IP and can undermine incentives for innovation.

Within the life sciences arena, the grounds for issuing a compulsory license in India under the Patents Act, 1970 are broad, vague and appear to include criteria that are not clearly related to

¹¹³ Id. at ¶ 4.4.1.
¹¹⁴ Id. at ¶¶ 4.2, 4.4.3.
¹¹⁶ Id.
legitimate health emergencies. Internationally, in various multilateral fora, India has advocated for the broad adoption and implementation of legislation that facilitates the use of compulsory licenses, contrary to the spirit of the TRIPS Agreement. A market with ongoing threats of compulsory licenses perpetuates an unreliable environment for patent protection and investment.

**Lack of Regulatory Data Protection and Patent Linkage**

The Indian Regulatory Authority relies on test data submitted by originators to another country when granting marketing approval to follow-on pharmaceutical products. This indirect reliance results in unfair commercial use prohibited by TRIPS and discourages the development of new medicines that could meet unmet medical needs.

State regulatory authorities in India can grant marketing approval for a generic version of a new medicine after four years have passed since the new medicine was first approved. State regulatory authorities are not required to verify or consider the remaining term of any existing patents. IPO supports development of a notification and early resolution mechanism for patent disputes to give innovators security in knowing that their efforts in creating a new drug will be respected for the duration of the patent period.

**Local Working Requirements**

Patent holders risk compulsory licensing if they fail to “work” their inventions in India within three years of the respective patent grant.\(^\text{117}\) This appears to include situations when patent holders import the related technology into the country, but do not locally manufacture it. It is difficult to understand how this complies with TRIPS, which requires patents and their associated rights to be available “without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.”\(^\text{118}\) Among those rights is the ability to exclude others from making, using, or selling their invention.\(^\text{119}\)

To facilitate potential licensing activity, the Controller of Patents is empowered to require patent holders and any licensees to provide details on how the invention is being worked in India.\(^\text{120}\) Statements of Working (Form 27) must be provided annually.\(^\text{121}\) Failure to provide the requested information is punishable by fine.\(^\text{122}\) Although the Form-27 was amended to relax certain details required to be furnished, the Statement is still very much required to be filed on an annual basis and is still onerous to complete.\(^\text{123}\)

The push to enforce the submission of Statements of Working is thought to increase the availability of compulsory licensing. The subsequent publication of the statements in a

\(^\text{117}\) *The Patents Act, 1970*, Section 84(1)(c).

\(^\text{118}\) *TRIPS*, Art. 27.1 (emphasis added).

\(^\text{119}\) *TRIPS*, Art. 28(1).

\(^\text{120}\) *The Patents Act, 1970*, Section 146.


\(^\text{122}\) *The Patents Act, 1970*, Section 122 (1).

\(^\text{123}\) *See Patents (Amendment) Rules, 2020*,

standalone database is further evidence of that intention. Form 27 is also extremely burdensome, including requests concerning the value of the products worked and the licenses or sub-licenses that are granted for a given patent. Not only might it be difficult to provide such information, but this also forces patent holders and their licensees to potentially provide confidential business information to the government and public. Currently, there is no mechanism to submit the information with a request for confidentiality and to avoid the information from becoming public after filing.

The emphasis on Form 27 suggests that India could impose compulsory licenses on users of its patent system even if the relevant product is available in India, if it is not manufactured there. India issued its first compulsory license for a pharmaceutical drug in 2012, which survived several legal challenges including at the Supreme Court of India. Most troubling about the decision was the interpretation that, at least in some circumstances, the working requirement might not be fully satisfied through importation. In many cases it would be impractical, if not impossible, for patent holders or licensees to manufacture in every country around the world. The ability to make commercial choices with respect to manufacturing is imperative, both in terms of preserving competitiveness and reducing the cost of critical technologies. While the revised Form-27 does seek separate data about the revenues generated from the import and manufacturing in India, a clarification must be provided that availability only through import does satisfy the requirement of working in India.

In a welcome move, the Parliamentary Committee in its July 2021 Report had recommended the “Department to consider relaxing the requirement to furnish information under the form on a yearly basis to ease the compliance burden on universities, R&D institutions, startups and small enterprises.” Relief from this requirement, however, should be given to all IP owners, from independent inventors to innovators with large research and development programs, without discrimination. In its Response (recorded in the April 2022 Report), however, it appears that the government has been able to satisfy this recommendation by showing the recent changes in Form-27.

**Patent Examination**

IPO suggests that the Indian Patent Office implement measures to improve the speed of the review process for patent applications while also improving the quality of patent examination. In its Report of August 2022, the Economic Advisory Council to the Prime Minister has specifically raised the issue of general delay in disposal of patent applications and reasonably linked it with lack of Controller level examiners (which are only 247 in India). Accordingly, IPO suggests that induction and training of Examiners and Controllers be carried out to bridge the gap.

Further, the law and practice with respect to allowability of divisional applications in India is restrictive. In the divisional application, the Applicants are not permitted to claim the subject matter disclosed but not claimed in the parent application. It is therefore recommended that

---

124 Intellectual Property Appellate Board, *Bayer Corporation v. Union of India through the Secretary & Ors.*, Order No. 45, ¶ 52 (Mar. 2013); see also *Bayer v. Union of India*, Writ Petition No. 1323 of 2013, at 48.
necessary changes be made in law as to allow the applicants to strategically obtain protection of multiple aspects of their invention in India similar to other jurisdictions.

It is a positive development, India entered into its first ever PPH (Patent Prosecution Highway) Program with the Japan Patent Office in 2019. In December 2021, this program entered into its third year. In its April 2022 Report, the Parliamentary Committee also noted that that a working group has been formed for a new PPH program with Denmark. IPO hopes that India enters into PPH arrangements with other IP Offices.

The Need to Upgrade Trade Secret Protection

India lacks civil and criminal statutory protection for trade secrets. Contractual obligations provide the primary vehicle for protecting trade secrets. Although other means of protection might exist, such as suing under the tort of “breach of confidence,”125 each has a common shortcoming: requiring a close relationship between the trade secret owner and the would-be misappropriator. Bad actors who choose to steal information rather than innovate are often not in privity with trade secret owners.

There are significant benefits to collaborating with Indian firms, especially in light of the country’s highly skilled services sector. Stakeholders in the U.S. and India would mutually benefit from stronger and more transparent trade secret protection, covering a broader range of actors.

Moves by the Indian government indicate that the country might value such an approach. Recently, in response to the Parliamentary Committee recommendation (in its 161st Report of 2021) regarding “enacting a separate legislation or a framework for protection of trade secrets,”126 the government confirmed that “Department is consulting stakeholders on the same for implementation.”127 IPO is also encouraged by the commitment at the 2015 U.S. and India Trade Policy Forum to deepen cooperation on trade secrets.128 There is also a recommendation included in India’s National IPR Policy to study trade secret protection, with an aim for further policy development.129 Earlier recognition of the need to improve trade secret protection can be

129 National IPR Policy, at ¶3.8.4.
found in the 2008 draft National Innovation Act and 2012 draft National IPR Strategy. There is also a growing body of academic literature originating within India that agrees that improving trade secret protection is critical. The 2012 draft National IPR Strategy made the point when it explained that a “predictable and recognizable trade secret regime will improve investor confidence,” although this was not included in the approved version of the National IPR Strategy. IPO agrees that a national trade secret law that provides sufficient protection against all potential misappropriators, injunctive relief, preservation of evidence, the ability to secure damages, and effective deterrence to prevent acts of theft in the first place, is an important step.

**Disclosure of Foreign Filings**

Section 8 of India’s Patent Act requires disclosure and regular updates on foreign applications that are “the same or substantially the same invention.” The original purpose of the requirement was to ensure high quality patents were issued by India, in light of patent examinations around the world. Although this might have been necessary when the Patent Act was originally enacted almost 50 years ago, patent examiners now have access to file histories for applications in many jurisdictions. In fact, given India’s appointment as an International Search Authority for the Patent Cooperation Treaty (PCT), it is possible that the requirement to furnish examination results for co-pending applications conflicts with PCT rules. However, failure to provide the required information can result in devastating consequences to the patent applicant. Non-compliance provides an independent ground for pre- and post-grant opposition, as well as revocation. Furthermore, in the absence of clarity regarding the meaning of “substantially the same invention,” in many cases, it is difficult to be certain about full compliance with this requirement.

Failure to comply with section 8 is now a commonly cited ground to invalidate patents. Patentees must worry about co-pending family members as well as other similar patents. The requirements set forth by section 8 are antiquated and create unnecessary uncertainty and expense for patent applicants, particularly when the Indian Patent Office, which is also an ISA, is equipped to search and find all the patent applications in the concerned patent family. This is
rightly pointed out in the Report of Economic Advisory Council to the Prime Minister that since India is a member of WIPO CASE (Centralized Access to Search and Examination), this cumbersome compliance requirement should be done away with, at least for the PCT national phase applications.\(^{138}\)

**Foreign Filing Permissions and the Ministry of Defense**

India’s Patent Act requires that an invention having a resident Indian inventor should not make or cause to make any patent application outside India unless a Foreign Filing Permission (FFP) is obtained from the Indian Patent Office.\(^{139}\) Non-compliance with this requirement results in monetary fine or a jail term or both.\(^{140}\) While the routine FFPs are granted very expeditiously by the Indian Patent Office, which is appreciated, in case the Indian Patent Office concludes that the subject matter of an invention is relevant for defense purposes or atomic energy, the matter is referred to Ministry of Defense (MoD) for its prior consent. IPO understands that the MoD can take up to two years to grant consent. This delay is extremely detrimental to obtaining FFP. Applicants might lose their application priority date and have no ability to contest the Patent Office’s decision.

**New Rules for Patent Suits and other IP matters before IP Division of Delhi High Court**

In a progressive move, on February 24, 2022, after few rounds of comments and inputs from stakeholders, the Delhi High Court published “The High Court of Delhi Rules Governing Patent Suits, 2022” (Patent Suit Rules)\(^{141}\) and “The Delhi High Court Intellectual Property Rights Division Rules, 2022” (IPD Rules).\(^{142}\) These Rules streamline the procedure for conducting the proceedings for Patents (infringement and cancellation) as well as other IP matters in a time-bound manner before the newly constituted IP Division of Delhi High Court. Procedures for summary adjudication, litigation hold notice, hot-tubbing,\(^{143}\) constitution of confidentiality clubs, early neutral evaluation, etc. have been introduced. While the matters from the IPAB (now abolished) are now being listed before the IP Divisions, it will be interesting to see how the large backlogs will be tackled.

**IP Oppositions and Enforcement**

While the timeframes for prosecution and grant of patents as well as trademarks have reduced, disposal of contentious proceedings, such as opposition and cancellation proceedings, as well as litigation matters addressing the merits, can still be lengthy. Specifically the pre-grant oppositions to patent applications, which can be filed anytime until grant, have created

---


\(^{139}\) *The Patents Act*, (1970), Section 39.

\(^{140}\) Id. at § 118.

\(^{141}\) “The High Court of Delhi Rules Governing Patent Suits, 2022” [Patent Suit Rules, 2022] [https://egazette.nic.in/WriteReadData/2022/233727.pdf](https://egazette.nic.in/WriteReadData/2022/233727.pdf)

\(^{142}\) “The Delhi High Court Intellectual Property Rights Division Rules, 2022” [DHC-IPD Rules, 2022] [https://egazette.nic.in/WriteReadData/2022/233739.pdf](https://egazette.nic.in/WriteReadData/2022/233739.pdf)

\(^{143}\) Two or more fact or expert witnesses being questioned together. Practice originated in arbitration proceedings.
uncertainty and delayed the introduction of new inventions by delaying patent prosecution and undermining patent office efficiency.

**Stakeholder Consultation to discuss key issues related to design registrations in India**

In a welcome move, the Government of India conducted a stakeholder consultation meeting in June 2022 to discuss some of the key issues related to registration of industrial designs in India, including: (i) extension of term of protection for designs from 15 to 25 years; (ii) protection of unregistered designs in India; (iii) adequacy of grace period under the designs law; (iv) India’s accession to Hague Convention for international registration of designs; (v) removal of restrictions for protection of designs under copyright law; (vi) protection of activities of exporting, stocking, and using under the designs law; and (vii) protection of graphic symbols, logos, and graphical user interfaces (GUIs) under designs law; and (viii) restrictive requirement of filing design embodiments in the applications. It will be interesting to monitor how the design law in India is amended to address these issues.

**Genetic Resources and Traditional Knowledge**

India’s Patents Act requires applicants to disclose the source and geographical origin of biological materials used to make an invention that is the subject of a patent application. Failure to correctly identify the geographical source of a biological material is a ground for pre-grant and post-grant oppositions as well as revocation proceedings. Further, even when the origin of the source of biological material is not India, the Applicants are required to identify the specific location / city of origin, which is onerous and unwarranted. These special disclosure requirements and the scope of what constitutes a genetic resource are at best ambiguous, subjecting the validity of valuable patent rights to damaging uncertainty. Thus, IPO believes that these requirements should be deleted.

**INDONESIA**

**Genetic Resources and Traditional Knowledge**

Indonesia’s 2016 Patent Law imposes patent disclosure requirements regarding the source and origin of genetic resources or traditional knowledge related to inventions. Such requirements introduce uncertainties into the patent system that inhibit innovation in relevant technologies and undermine the potential of benefit-sharing. The current proposed amendments to the Patent Law do not adequately address this concern and IPO believes that these disclosure requirements should be eliminated.

**MEXICO**

**Divisional applications under the New IP Law**

Provisions for divisional applications changed in the new Mexican IP Law (LFPPI), which entered in force on November 5, 2020. Now voluntary divisional applications can only derive from a parent case and cannot derive from another divisional application. Thus, voluntary divisional applications deriving from divisional applications are not allowed, unless that the
Mexican PTO (IMPI) determines that said divisional is allowable. In case the Examiner issues a unity of invention objection in a divisional application, the applicant can still file a divisional from said previous divisional in which unity of invention was objected.

Ordinarily, these changes ought not be a problem for divisional applications filed after November 5, 2020, that derive from a divisional that was filed before November 5, 2020, since it is clear in Mexican law and Constitution that laws (statutes), and provisions within them, cannot be applied retroactively. The Mexican Patent Office (IMPI) previously applied these new provisions to divisional applications that should be governed by the former law and therefore divisional applications based on priority applications filed under the old law were being objected to through Official Actions. However, this situation has been overcome as of May of 2022 and now cascade divisionals that derive from a parent case filed before November 5, 2020 are no longer being objected to.

**Supplementary Certificate of life term correction due to delays in prosecution.**

On a positive note, the IP Law (LFPPI) that entered in force in Mexico on November 5, 2020 includes a mechanism to adjust patent terms (for patents filed on or after that date) to recover up to five years of term lost due to unreasonable delays by IMPI in prosecuting and granting patents by way of a “supplementary certificate.” The supplementary certificate is only available if the time between filing and grant exceeds five years. The mechanism, however, does not provide an automatic patent term adjustment, but rather requires that the applicant file a request, fees, and a supporting brief, which is unduly burdensome given that IMPI has in its possession all information necessary to compute the unreasonable delay.

**Enforcement of Pharmaceutical or Biologics Patents**

The temporality of 8 years for biologics patents and 3 years for chemical patents in the Roche-Bolar exception were removed in the new law. However, the health law regulations have not yet been amended accordingly. The regulations should be amended to be consistent with the law.

**Post Grant Amendments**

The new IP law establishes that no post grant amendments can be made to granted patents that are subject to review, if the validity of the patents is previously questioned. This limitation was not present in previous law.

**RUSSIA**

The 2022 Special 301 Report placed Russia on the Priority Watch List. It also noted that “the ability of the Office of the U.S. Trade Representative to raise and resolve intellectual property (IP) protection and enforcement issues in Russia is severely limited.” IPO offers the following comments regarding Russia, expecting that this limitation on the ability to raise and resolve IP
issues likely remains, and understanding that U.S.-Russia trade has significantly decreased, but also recognizing that USTR may again want to identify Russia in its Report.

**Russian Law Fails to Provide Adequate Trade Secret Protection**

Russia offers nominal and weak protection for trade secrets, leaving little protection for American innovators doing business in the country. Russian law requires a trade secret holder to introduce a “regime of commercial secrecy” to protect its know-how. Although this law sounds similar to the “reasonable steps” in TRIPS, which exist in many countries, in reality it is a rigid regime that places an unrealistic burden on the people it is meant to protect. Russian law only provides protection to trade secret holders that have complied with a specific set of requirements, including providing a specific inventory of the information to be protected and an up-to-date record of those with access to the information. The trade secret must be marked as both confidential and with the full name and address of the owner. Such prerequisites for protection often fail to correspond with the commercial realities of most businesses. For example, an inventory might be impossible to create considering new trade secrets might be created daily, and many types of trade secrets might be difficult or impossible to mark as required by the law. In practice, these formalities could cause businesses to grind to a halt instead of offering any meaningful protection.

Enforcement tends to be inadequate as well. Although preliminary remedies such as injunctions and seizures are available for some types of intellectual property, such as injunctions and seizures in domain and parallel import disputes, Russian courts rarely issue injunctions in patent cases and never in trade secret misappropriation cases. Criminal penalties are lacking, often limited to community service — despite significant losses for the trade secret owner. Considering these shortcomings, the APEC Best Practices for Trade Secret Protection and Enforcement, which Russia endorsed as part of a 2016 APEC declaration, should be implemented.

**Challenges to Patent Protection**

On December 31, 2020, the Russian Government adopted Decree No. 3718-p, which in accordance with the current provisions of Article 1360 of the Russian Civil Code, granted a compulsory license to a local generic company, Pharmasyntez, to produce a patent protected product, — antiviral medicine Remdesivir. The patent holder challenged the Decree in the Supreme Court arguing that it breaches the IP rights and contradicts applicable national legislation and international conventions. In May 2021, the Supreme Court ruled against the patent holder, confirming the validity of the Decree. In parallel there is an ongoing trend of

local generic companies applying for compulsory licenses on innovative drugs pursuant to the Article 1362 of the Russian Civil Code.

In April 2021, the Russian Government adopted new legislation amending Article 1360 of the Russian Civil Code and introducing new rules on patent usage in the interest of national security. New rules expand the government’s discretion to issue a permit to use the invention, utility model, or industrial design “to ensure national security or protect human lives or health, in case of emergency” without the consent of the patent holder, but with a notice and compensation approved by the Government. Current wording mentioning healthcare as one of the grounds for issuing the permit opens the door to applying these rules to patents on innovative medicines and healthcare products.

In March 2022, in response to the sanctions taken against Russia following the invasion of Ukraine, Russia introduced measures to substantially lessen IP protections for foreign companies from “unfriendly countries.” “Unfriendly countries” included any country that supports sanctions. One decree set a 0% compensation for the “government compulsory licensing” of inventions if the patent holder has the citizenship of or place of registration/primary business/primary profit in an “unfriendly state.” Another measure allows parallel import, i.e. importation without the consent of the IP rights holders, of certain goods according to a list adopted by the Ministry of Industry & Trade (MoIT). In combination with the possibility of importing medicines in foreign packaging (with a self-adhesive label in Russian), the basic conditions have thus been created for allowing parallel importing of individual (or all) medicines. In addition, trademark rights are not exempt from the danger of being used without permission or compensation, and it has been reported that Russian applicants have filed Russian trademark applications copying well-known U.S. marks.

VIETNAM

Long Trademark Application Pendency

Vietnam has a particularly long pendency (764 days) for trademark registration applications,148 which creates substantial headwinds for brand owners with a negative impact on U.S. trade. At best, excessive pendency increases ambiguity and prosecution costs. At worst, it leads to delays in product launches and or significant rebranding costs should the applied for marks ultimately not register.

III. PUSH TO WEAKEN IP RIGHTS WITHIN MULTILATERAL FORA

IP protection continues to come under fire in multilateral fora. Such efforts are largely based on misinformation about the impact of IP rights on innovation and technology diffusion. The principal argument is that IP systems are a barrier that needs to be dismantled if countries with developing economies are to advance. Yet, this argument does not accurately reflect the

contribution of IP to innovation, socio-economic growth, and technology diffusion in the real world. It ignores that the IP system has supported life-changing innovations across all sectors for decades and that there is no empirical evidence that IP rights are a barrier to advancement.\(^\text{149}\)

Multilateral organizations, notably WIPO, but also the World Trade Organization (“WTO”) and World Health Organization (“WHO”), play an important role in ensuring the existence of robust evidence about the contribution of IP systems to innovation and technology diffusion. They also have the responsibility to push back on erroneous and misleading statements about how IP works in practice. However, this has become extremely difficult due to intense political engagement by several countries in these “member-driven” organizations. Many countries aggressively orient work programs and discussions towards IP weakening. They seek technical assistance, analysis, and recommendations in favor of compulsory licensing, unduly restrictive patentability criteria, and lack of enforcement. Such efforts align with their industrial strategies, aimed at obtaining proprietary technologies at reduced cost.

Activities in these bodies can influence legislation. Unfortunately, misguided modifications of IP systems, like those discussed in many of these bodies, can lead to significant uncertainty, a lessening of the incentives necessary to support innovative efforts, and ultimately, severe disadvantages for U.S. industry. Considering the wide range of bodies attempting to chip away at the global IP framework that is needed to enable a level playing field for innovations, a robust U.S. interagency process is necessary to effectively monitor U.S. interests in this regard. And, more importantly, sustained U.S. leadership is critical to encourage these bodies to recognize that IP turns ideas into innovative products, exports, and jobs.

IPO strongly supports equitable, widespread, and successful distribution of vaccines and other measures necessary to meet the challenges of COVID-19. As a world, we have asked our innovative industries to find solutions to help us battle COVID-19. They have done so and continue to do so, in many cases building on innovations that have been developed over the years for other purposes based on extensive research and development.

IPO was disappointed in the June 2022 WTO Ministerial Decision on the Agreement on Trade-Related Aspects of Intellectual Property Rights that applied to COVID-19 vaccines. A stable and predictable IP framework is crucial to investors, inventors, and others who take the necessary risks to bring needed technology innovations to the marketplace.

IPO welcomes the extension of the deadline to decide whether there should be a modification of the TRIPS agreement to cover the production and supply of COVID-19 diagnostics and therapeutics — and USTR requesting that the United States International Trade Commission launch an investigation into COVID-19 diagnostics and therapeutics and provide information on market dynamics to inform the discussion around supply and demand, price, and production and access. IPO believes that taking the time to review the evidence will demonstrate that the suggestion that the WTO should change the existing, long-established IP framework as it applies to COVID-19 diagnostics and therapeutics is mistaken.

In summary, IPO believes that discussions regarding the IP system in multi-lateral bodies, such as the WTO, the WHO, and WIPO, should always be evidence-based. IPO believes that, when this is the case, the evidence will show that IP facilitates innovation, as well as voluntary and successful partnerships, that help, not hinder, society’s efforts to meet global challenges.

IPO thanks the USTR for permitting IPO to provide comments and would welcome any further dialogue or opportunity to provide additional information to assist your efforts in developing the 2023 Special 301 Report.

Sincerely,

Karen Cochran
President